<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523421002117</prism:url><dc:identifier>doi:10.1016/j.ejmech.2021.113362</dc:identifier><eid>1-s2.0-S0223523421002117</eid><prism:doi>10.1016/j.ejmech.2021.113362</prism:doi><pii>S0223-5234(21)00211-7</pii><dc:title>Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>218</prism:volume><prism:startingPage>113362</prism:startingpage><prism:pageRange>113362</prism:pagerange><articleNumber>113362</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2021-06-05</prism:coverdate><prism:coverDisplayDate>5 June 2021</prism:coverdisplaydate><prism:copyright>© 2021 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Wang, Xuebao</dc:creator><dc:creator>Wu, Kaiqi</dc:creator><dc:creator>Fang, Longcheng</dc:creator><dc:creator>Yang, Xiaojiao</dc:creator><dc:creator>Zheng, Nan</dc:creator><dc:creator>Du, Zongxuan</dc:creator><dc:creator>Lu, Ying</dc:creator><dc:creator>Xie, Zixin</dc:creator><dc:creator>Liu, Zhiguo</dc:creator><dc:creator>Zuo, Zhigui</dc:creator><dc:creator>Ye, Faqing</dc:creator><dc:description>
                  Signal transducer and activator of transcription 3 (STAT3) has been confirmed as an attractive therapeutic target for cancer therapy. Herein, we designed and synthesized a series of N-substituted Sulfamoylbenzamide STAT3 inhibitors based on small-molecule STAT3 inhibitor Niclosamide. Compound B12, the best active compound of this series, was identified as an inhibitor of IL-6/STAT3 signaling with an IC50 of 0.61–1.11 μM in MDA-MB-231, HCT-116 and SW480 tumor cell lines with STAT3 overexpression, by inhibiting the phosphorylation of STAT3 of Tyr705 residue and the expression of STAT3 downstream genes, inducing apoptosis and inhibiting the migration of cancer cells. Furthermore, in vivo study revealed that compound B12 suppressed the MDA-MB-231 xenograft tumor growth in nude mice at the dose of 30 mg/kg (i.g.), which has better antitumor activity than the positive control Niclosamide. More importantly, B12 is an orally bioavailable anticancer agent as a promising candidate for further development.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>N-substituted sulfamoylbenzamide STAT3 inhibitors</dcterms:subject><dcterms:subject>Niclosamide</dcterms:subject><dcterms:subject>Anti-tumor activity</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523421002117" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523421002117" rel="scidir"/></link></coredata><objects><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="725" height="262" size="37120">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="691" height="342" size="58807">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="121" height="87" size="3103">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="455" size="62094">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="308" size="24633">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="691" height="378" size="39499">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="711" height="725" size="66657">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="135" height="68" size="3131">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="332" size="78232">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="164" size="13536">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="ga1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="477" height="200" size="30690">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-ga1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="313" height="282" size="13413">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="691" height="381" size="169146">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="201" size="19602">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="2845">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="8116">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="158" size="3556">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="193" height="164" size="12802">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="206" height="164" size="11248">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="120" size="5030">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="161" height="164" size="4566">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="110" size="3065">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="136" size="26911">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="7824">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="ga1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="92" size="7914">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-ga1.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="182" height="164" size="4877">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="121" size="25591">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="11938">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3209" height="1158" size="272541">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3059" height="1512" size="469923">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="536" height="387" size="21933">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="2014" size="498206">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1719" height="1365" size="202562">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3060" height="1676" size="368995">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3149" height="3211" size="512202">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="599" height="300" size="20818">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="1471" size="718342">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1720" height="727" size="108600">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="ga1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2111" height="886" size="224675">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-ga1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1386" height="1247" size="98916">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3060" height="1688" size="1528218">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1719" height="889" size="168652">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="34110726">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-mmc1.docx?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1341712">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421002117-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85103334873</scopus-id><scopus-eid>2-s2.0-85103334873</scopus-eid><pubmed-id>33774344</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85103334873" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210317">2021-03-17</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210317">2021-03-17</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210325">2021-03-25</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210325">2021-03-25</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-05-02T12:43:18</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523421002117</xocs:eid>
      <xocs:pii-formatted>S0223-5234(21)00211-7</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523421002117</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2021.113362</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523421X00074</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210511">2021-05-11T07:52:39.478936Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20210605</xocs:date-search-begin>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1616000264">2021-03-17T16:57:44.939707Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid nomenclature primabst ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>218</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>218</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 218</xocs:vol-iss-suppl-text>
      <xocs:sort-order>13</xocs:sort-order>
      <xocs:first-fp>113362</xocs:first-fp>
      <xocs:article-number>113362</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>113362</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20210605</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>5 June 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-06-05</xocs:cover-date-start>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2021 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DISCOVERYNSUBSTITUTEDSULFAMOYLBENZAMIDEDERIVATIVESNOVELINHIBITORSSTAT3SIGNALINGPATHWAYBASEDNICLOSAMIDE</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>WANG</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>X</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:nomenclature">
            <xocs:item-toc-section-title>Abbreviations used</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and Discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological evaluation</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell viability assay and SAR analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Inhibitory effect of STAT3 tyrosine phosphorylation</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>The selectivity of compound B12 to STAT3</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound B12 could inhibit promoter activity of STAT3</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound B12 induced apoptosis and caused changes in related apoptotic proteins</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound B12 reduced tumor cells colony formation in vitro</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound B12 inhibited migration of cancer cells in vitro</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound B12 inhibited tumor growth in a mouse breast cancer model</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthetic routes of N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-sulfamoylbenzamide (NGT 02)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthetic routes of compound a series, B series and X series</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Synthetic routes of compound Y series and Z series</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Oil-water partition coefficient (logP) measurement experiment</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cell lines and reagents</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cell viability assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>STAT3 kit</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>IL-6 induction of STAT3 phosphorylation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Kinase inhibition assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Transient transfection and dual luciferase reporter assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>Flow cytometry analysis of apoptotic cells</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.11</xocs:item-toc-label>
               <xocs:item-toc-section-title>Colony survival assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.12</xocs:item-toc-label>
               <xocs:item-toc-section-title>Transwell assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.13</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vivo studies</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>172</xocs:ref-first-fp>
            <xocs:ref-last-lp>186</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>MIKLOSSY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>611</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>825</xocs:ref-first-fp>
            <xocs:ref-last-lp>833</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1202</xocs:ref-first-fp>
            <xocs:ref-last-lp>1212</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>YAMAMOTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>24</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>HE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-article-number>e0175466</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>LIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>70</xocs:ref-first-fp>
            <xocs:ref-last-lp>77</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>354</xocs:ref-first-fp>
            <xocs:ref-last-lp>361</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>HSIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1053</xocs:ref-first-fp>
            <xocs:ref-last-lp>1064</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>HUNG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>454</xocs:ref-first-fp>
            <xocs:ref-last-lp>465</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>JIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-article-number>e0147157</xocs:ref-article-number>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>917</xocs:ref-first-fp>
            <xocs:ref-last-lp>922</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>GAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>LING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>646</xocs:ref-first-fp>
            <xocs:ref-last-lp>651</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>JANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>526</xocs:ref-first-fp>
            <xocs:ref-last-lp>532</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>YOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>729</xocs:ref-first-fp>
            <xocs:ref-last-lp>739</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>X</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>909</xocs:ref-first-fp>
            <xocs:ref-last-lp>915</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>REN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>454</xocs:ref-first-fp>
            <xocs:ref-last-lp>459</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>CERLES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>300</xocs:ref-first-fp>
            <xocs:ref-last-lp>311</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>8</xocs:ref-first-fp>
            <xocs:ref-last-lp>14</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>WALTERSHAYGOOD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1377</xocs:ref-first-fp>
            <xocs:ref-last-lp>1385</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>CHIEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>659</xocs:ref-first-fp>
            <xocs:ref-last-lp>669</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4150</xocs:ref-first-fp>
            <xocs:ref-last-lp>4155</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>5292</xocs:ref-first-fp>
            <xocs:ref-last-lp>5304</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>180</xocs:ref-first-fp>
            <xocs:ref-last-lp>185</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>AVALLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>65</xocs:ref-first-fp>
            <xocs:ref-last-lp>72</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>GUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>752</xocs:ref-first-fp>
            <xocs:ref-last-lp>764</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>WANGX2021X113362</xocs:refkey3>
         <xocs:refkey4ai>WANGX2021X113362XX</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2023-03-25T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2023-03-25T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2021 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-03-06T03:56:49.960Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(21)00211-7</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523421002117</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523421002117</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2021.113362</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-05-11T07:52:39.478936Z</xocs:timestamp>
         <xocs:cover-date-start>2021-06-05</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/MAIN/application/pdf/bd9458cc38579451ece90b1fee2faa39/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2586583</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>15</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523421002117-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/PREVIEW/image/png/fe187c09ce451056106ffa8ff7a63487/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>63413</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/sc1/DOWNSAMPLED/image/jpeg/e450a3fcc6b4f0007a7754043e5c5ade/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37120</xocs:filesize>
               <xocs:pixel-height>262</xocs:pixel-height>
               <xocs:pixel-width>725</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr6/DOWNSAMPLED/image/jpeg/8973e8cda3fb5cf5d097af238844529b/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>58807</xocs:filesize>
               <xocs:pixel-height>342</xocs:pixel-height>
               <xocs:pixel-width>691</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/fx2/DOWNSAMPLED/image/jpeg/164b05ab4eb432f8520d47e3a2555d2c/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3103</xocs:filesize>
               <xocs:pixel-height>87</xocs:pixel-height>
               <xocs:pixel-width>121</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr9/DOWNSAMPLED/image/jpeg/d22c0fbfa0f61e7c26bcbeea32772b7f/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>62094</xocs:filesize>
               <xocs:pixel-height>455</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr2/DOWNSAMPLED/image/jpeg/51b706a4f352369ecdb30f1737db7742/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>24633</xocs:filesize>
               <xocs:pixel-height>308</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr1/DOWNSAMPLED/image/jpeg/5c1adf6b2e1d6ac1f0c95f2999c6a950/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39499</xocs:filesize>
               <xocs:pixel-height>378</xocs:pixel-height>
               <xocs:pixel-width>691</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/sc2/DOWNSAMPLED/image/jpeg/daf24a16e1ae2b4c922e9241a1f6938f/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>66657</xocs:filesize>
               <xocs:pixel-height>725</xocs:pixel-height>
               <xocs:pixel-width>711</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/fx1/DOWNSAMPLED/image/jpeg/73d42ad31ed5458979d6dd6d04f17fc7/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3131</xocs:filesize>
               <xocs:pixel-height>68</xocs:pixel-height>
               <xocs:pixel-width>135</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr7/DOWNSAMPLED/image/jpeg/2461a7e1145f9c89b99a1b16cd3ddb92/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>78232</xocs:filesize>
               <xocs:pixel-height>332</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr3/DOWNSAMPLED/image/jpeg/1a32723b655ba4a0401e16a43aa508e0/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>13536</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-ga1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/ga1/DOWNSAMPLED/image/jpeg/fdbe6f4b19af0e8272dcc6aaf06544c8/ga1.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30690</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>477</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr4/DOWNSAMPLED/image/jpeg/cc4d31743751c64b619b7f9e309c6f27/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>13413</xocs:filesize>
               <xocs:pixel-height>282</xocs:pixel-height>
               <xocs:pixel-width>313</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr8/DOWNSAMPLED/image/jpeg/626e89e8afe9ad4a6969185c67823325/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>169146</xocs:filesize>
               <xocs:pixel-height>381</xocs:pixel-height>
               <xocs:pixel-width>691</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr5/DOWNSAMPLED/image/jpeg/28248c5fb01b05638693e217ee7dfbf0/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19602</xocs:filesize>
               <xocs:pixel-height>201</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/sc1/THUMBNAIL/image/gif/bd7d8813ed9592ebccdefd792e94b42a/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2845</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr6/THUMBNAIL/image/gif/2198c8f0f4cb0c70c7d0e5db804c57d0/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8116</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/fx2/THUMBNAIL/image/gif/909d25bb32e28bd0125b6127b8f4a816/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3556</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr9/THUMBNAIL/image/gif/603a539764f09e4b737d12665e374bc7/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12802</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr2/THUMBNAIL/image/gif/5b5f87c81836fa405baed4b95fc2b8eb/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11248</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>206</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr1/THUMBNAIL/image/gif/e5a858638ccd92e437051ccc4e823976/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5030</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/sc2/THUMBNAIL/image/gif/161896ebd0b3b856fa62e0a5a30aeb31/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4566</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>161</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/fx1/THUMBNAIL/image/gif/23d199021a1673b07b8d9ac3e530bdd9/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3065</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr7/THUMBNAIL/image/gif/45e3932c2e1fb56995140aa5c5a263b6/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>26911</xocs:filesize>
               <xocs:pixel-height>136</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr3/THUMBNAIL/image/gif/24edea387bb8f6dd81e83af512b26664/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7824</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-ga1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/ga1/THUMBNAIL/image/gif/923cd905b1f3384ad35e2e94254b6bf9/ga1.sml</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7914</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr4/THUMBNAIL/image/gif/844d989194913d5c4efaadf5f515aa0f/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4877</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>182</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr8/THUMBNAIL/image/gif/09f6ecdcc26d9578d791598b88b1e681/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>25591</xocs:filesize>
               <xocs:pixel-height>121</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr5/THUMBNAIL/image/gif/0b59b148075198fb76ed14936639e3e3/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11938</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/sc1/HIGHRES/image/jpeg/d5ea5c9576d16ff51c43bc8c0e138e27/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>272541</xocs:filesize>
               <xocs:pixel-height>1158</xocs:pixel-height>
               <xocs:pixel-width>3209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr6/HIGHRES/image/jpeg/0105ee82f8f17bc2239d6beb1aad173b/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>469923</xocs:filesize>
               <xocs:pixel-height>1512</xocs:pixel-height>
               <xocs:pixel-width>3059</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/fx2/HIGHRES/image/jpeg/35d19c704bc78517432a83f70ebee2f0/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21933</xocs:filesize>
               <xocs:pixel-height>387</xocs:pixel-height>
               <xocs:pixel-width>536</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr9/HIGHRES/image/jpeg/58ff479513fe616673bf206935a271aa/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>498206</xocs:filesize>
               <xocs:pixel-height>2014</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr2/HIGHRES/image/jpeg/08a77df707aff9970cdccce9f751a95f/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>202562</xocs:filesize>
               <xocs:pixel-height>1365</xocs:pixel-height>
               <xocs:pixel-width>1719</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr1/HIGHRES/image/jpeg/94a4888b370bc312d2f21c66a6e23aa7/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>368995</xocs:filesize>
               <xocs:pixel-height>1676</xocs:pixel-height>
               <xocs:pixel-width>3060</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/sc2/HIGHRES/image/jpeg/2ce69114cb5a23be8ab39a5b12686b93/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>512202</xocs:filesize>
               <xocs:pixel-height>3211</xocs:pixel-height>
               <xocs:pixel-width>3149</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/fx1/HIGHRES/image/jpeg/3b2fd5bff71392cbbbd4fb147e66f9f5/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20818</xocs:filesize>
               <xocs:pixel-height>300</xocs:pixel-height>
               <xocs:pixel-width>599</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr7/HIGHRES/image/jpeg/d28c64aaa57dfe3d424384c8504dd468/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>718342</xocs:filesize>
               <xocs:pixel-height>1471</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr3/HIGHRES/image/jpeg/f004018d0aafc45a370a0a3e2ee66880/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>108600</xocs:filesize>
               <xocs:pixel-height>727</xocs:pixel-height>
               <xocs:pixel-width>1720</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-ga1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/ga1/HIGHRES/image/jpeg/ef9dabb81d91f7aa1f9004a6773a55fd/ga1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>224675</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>2111</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr4/HIGHRES/image/jpeg/35f8e965b969fff372f9fee4ea5c56e3/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>98916</xocs:filesize>
               <xocs:pixel-height>1247</xocs:pixel-height>
               <xocs:pixel-width>1386</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr8/HIGHRES/image/jpeg/0d9ed0a7ae718b5323f96a75232933df/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1528218</xocs:filesize>
               <xocs:pixel-height>1688</xocs:pixel-height>
               <xocs:pixel-width>3060</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/gr5/HIGHRES/image/jpeg/1df59d7cdf71ff79cccf1a73529b20b4/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>168652</xocs:filesize>
               <xocs:pixel-height>889</xocs:pixel-height>
               <xocs:pixel-width>1719</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421002117/mmc1/MAIN/application/vnd.openxmlformats-officedocument.wordprocessingml.document/57308c6965364ff30507ad91deec9721/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>34110726</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421002117-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>1341712</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10T4G5Z5W4D/MAIN/application/pdf/0c647c8db74c02497e00d8423af80520/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>113362</aid>
            <ce:article-number>113362</ce:article-number>
            <ce:pii>S0223-5234(21)00211-7</ce:pii>
            <ce:doi>10.1016/j.ejmech.2021.113362</ce:doi>
            <ce:copyright type="full-transfer" year="2021">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Representative STAT3 small molecule inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523421002117/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Compound B12 inhibited STAT3 activation. (A and B) Western blot analysis of p-STAT3 (Y705), STAT3 and IL-6 induced p-STAT3 levels in whole-cell lysates of equal total protein prepared from MDA-MB-231 cells treated with compound B12 for 2 h. The results represent at least 3 independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523421002117/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">IL-6 induced STAT1 phosphorylation in MDA-MB-231 cancer cells. The MDA-MB-231 cells were serum-starved overnight, then left untreated or treated with B12 (1–10 μM) for 2 h, followed by stimulation by IL-6 (50 ng/mL). The cells were harvested at 45 min and analyzed by Western blot assays. The results represent at least 3 independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523421002117/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Compound B12 reduce STAT3 promoter activity by STAT3-mediated luciferase reporter activity in MDA-MB-231 cells. RLU: relative luciferase unit. (∗∗: p < 0.01; ∗∗∗, p < 0.001, compared with the DMSO group), the results represent at least 3 independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523421002117/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Effects of compound B12 on the expression of downstream gene, Bcl-xl and the levels of Cleaved-PARP, Cleaved-Caspase 3 and Cleaved-Caspase 9. Western blot analysis of Bcl-xl, Cleaved-PARP, Cleaved-Caspase 3 and Cleaved-Caspase 9 levels in whole-cell lysates of equal total protein prepared from MDA-MB-231 cells treated with compound B12 for 24 h. The results represent at least 3 independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523421002117/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Compound B12 induced MDA-MB-231 cancer cells apoptosis in Vitro. MDA-MB-231 cells were incubated with B12 at different concentrations (1–10 μM) or Niclosamide (10 μM) for 24 h. Annexin V/PI staining was carried out and the percentages of apoptotic cells were further determined using flow cytometry. ∗, p < 0.05 compared with the blank control group; ∗∗, p < 0.01; ∗∗∗, p < 0.001; compared with the positive control group, #, p < 0.05; ##, p < 0.01; ###, p < 0.001; the results represent at least 3 independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523421002117/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Compound B12 inhibited the colony formation of MDA-MB-231 cancer cells. MDA-MB-231 cells were treated with compound B12 at 0.1–1 μM or Niclosamide (10 μM) for 24 h and cultured for 14 d until the colonies were visible. Crystal violet solution was used to stain the colonies for 4 h and imaged. The results represent at least 3 independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523421002117/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Compound B12 inhibited Migration of MDA-MB-231 cancer cells in vitro. MDA-MB-231 cells were treated by B12 (0.1–1 μM) or Niclosamide (1 μM) and were allowed to migrate through the porous membrane for 24 h. Then cells in the upper surface of the chamber were completely removed and the lower surfaces of the membranes were stained with crystal violet solution for 20–30 min and imaged. The results represent at least 3 independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523421002117/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Effect of compound B12 and positive control Niclosamide on tumor weight and body weight of nude mice in MDA-MB-231 nude mice xenografts; (A) (B) tissue map of nude mice and nude mice xenografts; (C) Body weight of nude mice; (D) Weight of nude mice xenografts; ∗, p < 0.05 compared with the blank control group; ∗∗, p < 0.01; ∗∗∗, p < 0.001; compared with the positive control group, #, p < 0.05; ##, p < 0.01; ###, p < 0.001; the results represent at least 3 independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:href="pii:S0223523421002117/gr9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">The design based on Niclosamide</ce:simple-para>
                  <ce:simple-para id="fspara0060" view="all">Reagents and conditions: (i) SOCl<ce:inf loc="post">2</ce:inf>, 105 °C, 3–5 h; (ii) DIPEA, DCM, DMA, 0 °C, 12 h; (iii) 5% Pd–C, AcOEt, EtOH, H<ce:inf loc="post">2</ce:inf>, 20 °C, 8 h; (iiii) NaH, THF, N<ce:inf loc="post">2</ce:inf>, 20 °C, 12 h, 36–59%.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523421002117/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0065" view="all">Synthesis of compound NGT 02, A Series, B Series, X Series, Y Series and Z Series.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:href="pii:S0223523421002117/sc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1a" rowsep="0">
               <ce:label>Table 1a</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0010" view="all">Biological results and Structure-activity Relationship of NGT 02, A, B and X Series.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0080" role="short">Table 1a</ce:alt-text>
               <ce:link locator="fx1" xlink:href="pii:S0223523421002117/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="10">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <colspec colname="col10" colnum="10"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Comp.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">n</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">X</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HCT-116</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">SW480</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">L3.6</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col10" namest="col7" role="colgroup">(%) Inhibition (10 μM)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Niclosamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">91.54 ± 3.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">73.77 ± 3.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">76.81 ± 5.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">66.16 ± 5.51</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NGT 02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′-Cl-4′-NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">48.23 ± 5.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">63.98 ± 3.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−8.30 ± 2.77</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">44.73 ± 2.93</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.10 ± 0.93</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">40.34 ± 1.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.16 ± 2.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.70 ± 2.33</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">57.62 ± 6.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">51.35 ± 2.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.33 ± 1.57</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.21 ± 3.78</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">32.33 ± 4.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42.73 ± 3.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">38.41 ± 3.41</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.92 ± 2.66</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,5′-diOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">39.56 ± 5.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">47.14 ± 6.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">40.36 ± 4.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.19 ± 2.32</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′,5′-diOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">37.01 ± 4.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">46.39 ± 6.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">31.93 ± 2.81</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.52 ± 3.18</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">59.44 ± 6.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">57.74 ± 3.93</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.92 ± 3.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.51 ± 1.47</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42.79 ± 4.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">40.33 ± 4.73</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.81 ± 2.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.86 ± 3.21</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.16 ± 4.59</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">39.72 ± 3.48</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">34.41 ± 1.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.27 ± 1.18</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.42 ± 4.81</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.13 ± 2.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">38.13 ± 2.71</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.11 ± 1.73</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′-Cl-4′-NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43.22 ± 6.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.10 ± 1.92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">44.14 ± 3.63</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.29 ± 1.85</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">N</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42.85 ± 6.71</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.11 ± 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.33 ± 2.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">32.72 ± 2.49</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′,5′-diOCH<inf loc="post">3</inf>-2′-COOH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">52.13 ± 2.85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.14 ± 2.71</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.91 ± 3.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.32 ± 3.41</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A 13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-COOC(CH<inf loc="post">3</inf>)<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">91.12 ± 2.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">79.27 ± 2.53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">55.35 ± 5.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">31.23 ± 2.77</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.79 ± 3.27</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">37.34 ± 3.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">49.34 ± 5.73</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.91 ± 2.32</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42.39 ± 3.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43.04 ± 3.86</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.32 ± 1.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.28 ± 1.66</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.90 ± 2.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.25 ± 1.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">31.92 ± 2.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.79 ± 2.13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,5′-diOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">31.80 ± 1.84</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42.51 ± 3.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.22 ± 1.53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.33 ± 1.78</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′,5′-diOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.72 ± 3.53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.22 ± 1.68</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.19 ± 1.47</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.18 ± 1.37</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">93.26 ± 1.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">87.91 ± 2.33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">82.19 ± 3.62</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42.15 ± 2.90</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′-Cl-4′-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">41.49 ± 3.54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">47.53 ± 3.66</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">49.14 ± 2.84</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.22 ± 3.41</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-Cl-3′-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43.66 ± 5.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">44.14 ± 2.96</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">48.15 ± 3.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.42 ± 2.22</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">44.86 ± 4.84</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">45.38 ± 2.73</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.73 ± 4.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.18 ± 1.39</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.99 ± 3.93</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">41.36 ± 1.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42.93 ± 3.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.29 ± 2.16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.26 ± 2.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">55.35 ± 2.85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">47.39 ± 3.63</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.63 ± 1.33</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-COOC(CH<inf loc="post">3</inf>)<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">92.99 ± 2.93</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">85.28 ± 3.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">80.94 ± 4.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.86 ± 1.98</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′,5′-diOCH<inf loc="post">3</inf>-2′-COOH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">66.66 ± 6.75</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">47.24 ± 1.55</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.25 ± 1.87</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.81 ± 1.42</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-morpholinyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43.31 ± 2.85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">39.32 ± 2.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.91 ± 3.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.19 ± 2.37</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′,3′,4′,5′6′-perF</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33.10 ± 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">34.03 ± 1.71</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.13 ± 2.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.56 ± 1.48</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4’-(4′-methylpiperazin-1′-yl)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">37.30 ± 2.73</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">40.48 ± 2.41</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">38.33 ± 3.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.59 ± 0.74</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-SO<inf loc="post">2</inf>N(NH<inf loc="post">2</inf>)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">46.36 ± 3.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">41.33 ± 5.62</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.32 ± 1.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.12 ± 1.33</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′-SO<inf loc="post">2</inf>NH<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">52.76 ± 6.93</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">52.19 ± 6.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">34.29 ± 3.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.09 ± 0.37</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′-Cl-4′-NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">56.26 ± 3.48</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">49.45 ± 4.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">38.24 ± 4.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.35 ± 1.81</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′-OCH3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35.04 ± 4.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">50.05 ± 4.73</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42.83 ± 4.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.31 ± 0.41</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′-OCH3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">36.30 ± 6.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">64.17 ± 3.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">37.74 ± 2.69</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.42 ± 2.32</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-OCH3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">54.05 ± 4.44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43.15 ± 3.77</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.21 ± 1.52</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.02 ± 1.34</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′,3′-diCl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">51.55 ± 4.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">70.36 ± 6.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.62 ± 2.78</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.61 ± 1.59</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">44.42 ± 2.84</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">34.32 ± 2.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.42 ± 3.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">38.24 ± 2.43</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0015" view="all">The inhibitory effects of the compounds on the proliferation of the four cell lines were determined by the MTT assay. Results are expressed as means ± SD from three independent experiments.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1b" rowsep="0">
               <ce:label>Table 1b</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0020" view="all">Biological results and structure-activity relationship of Y and Z Series.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0090" role="short">Table 1b</ce:alt-text>
               <ce:link locator="fx2" xlink:href="pii:S0223523421002117/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="9">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Comp.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HCT-116</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">SW480</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">L3.6</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col9" namest="col6" role="colgroup">(%) Inhibition (10 μM)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Y1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-CH<glyph name="dbnd"/></glyph>CH<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.82 ± 0.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.20 ± 2.44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.91 ± 2.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−12.91 ± 1.72</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Y2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-C(CH<inf loc="post">3</inf>) = CH<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.84 ± 0.83</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.02 ± 2.71</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.27 ± 3.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−11.27 ± 1.95</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Y3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-CH<glyph name="dbnd"/></glyph>C(CH<inf loc="post">3</inf>)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.33 ± 2.41</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.14 ± 3.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.61 ± 1.66</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−7.12 ± 0.51</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Y4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.42 ± 4.82</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.22 ± 1.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.52 ± 2.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−15.17 ± 2.22</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Y5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.61 ± 3.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.19 ± 2.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.30 ± 1.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.47 ± 0.82</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Y6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(E)-CH<glyph name="dbnd"/></glyph>CHCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.42 ± 2.82</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.34 ± 1.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.61 ± 2.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.71 ± 2.17</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Z1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-phenyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.05 ± 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">32.29 ± 3.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.53 ± 2.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−27.84 ± 3.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Z2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′-methoxyphenyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.05 ± 1.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.24 ± 1.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33.92 ± 4.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−18.31 ± 1.46</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Z3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′-methoxyphenyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.51 ± 1.81</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.29 ± 1.75</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.97 ± 3.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−0.51 ± 0.71</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Z4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4′-methoxyphenyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.12 ± 2.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.80 ± 0.773</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.13 ± 2.95</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−18.30 ± 2.71</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Z5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′-nitrophenyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.27 ± 2.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.74 ± 1.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.12 ± 1.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−6.13 ± 0.85</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Z6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,5′-dimethoxyphenyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.11 ± 0.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−2.37 ± 1.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.12 ± 2.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−13.11 ± 1.41</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Z7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2′,6′-dimethoxyphenyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.13 ± 2.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.15 ± 1.62</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.63 ± 3.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.06 ± 0.81</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Z8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3′,4′,5′-triOCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6′-chloropyridin-3′-yl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.01 ± 0.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−9.17 ± 1.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.11 ± 2.38</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−15.72 ± 3.32</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0025" view="all">The inhibitory effects of the compounds on the proliferation of the four cell lines were determined by the MTT assay. Results are expressed as means ± SD from three independent experiments.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0030" view="all">Anti-proliferative activity of some designed compounds and reference Niclosamide.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0095" role="short">Table 2</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Comp.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">logP</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col6" namest="col3" role="colgroup">IC<inf loc="post">50</inf> ± SD (μM)<sup loc="post">a</sup>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HCT-116</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col6" namest="col5" role="colgroup">SW480</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Niclosamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.17 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.80 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.45 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">2.16 ± 0.19</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NGT 02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.41 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.68 ± 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.96 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.58 ± 0.52</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.22 ± 0.63</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.79 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.72 ± 0.66</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.69 ± 0.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.37 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.88 ± 0.52</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.54 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.70 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.82 ± 0.55</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">17.12 ± 0.81</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.19 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.07 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.64 ± 0.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">1.75 ± 0.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.76 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.32 ± 0.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.85 ± 0.66</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.83 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.61 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.69 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">1.11 ± 0.09</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.73 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.84 ± 0.62</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.25 ± 0.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.19 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.89 ± 0.81</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.15 ± 0.46</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.37 ± 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.31 ± 0.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.06 ± 0.52</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" nameend="col6" namest="col5" role="colgroup">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.77 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.34 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.63 ± 0.89</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">X4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.97 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.62 ± 0.53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0035" view="all">Note: a: SD: standard deviation; all experiments were independently performed at least three times.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="tspara0040" view="all">The IC<ce:inf loc="post">50</ce:inf> of three dominant compounds and Niclosamide in MDA-MB-231 cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0100" role="short">Table 3</ce:alt-text>
               <tgroup cols="2">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IC<inf loc="post">50</inf> ± SD (μM)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Niclosamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.21 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.92 ± 0.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.72 ± 0.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.23 ± 0.02</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl4" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="tspara0045" view="all">Kinase inhibition rate after treating with 10 μM B12.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0105" role="short">Table 4</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">RTK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">(%)Inhibition</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">RTK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">(%)Inhibition</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR (WT)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.41 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.33 ± 0.35</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR T790 M</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.23 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.20 ± 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR L858R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.82 ± 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MET</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.13 ± 0.02</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.99 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MEK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.56 ± 0.25</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.77 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ALK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.19 ± 0.34</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.24 ± 0.55</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">c-Kit</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.33 ± 0.26</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TYK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−1.53 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CDK7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.45 ± 0.42</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SRC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.42 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CDK1/CyCB1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−2.27 ± 0.26</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FGFR1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.58 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IGF1R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.93 ± 0.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FGFR2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.28 ± 0.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IKKβ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.87 ± 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FGFR3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.25 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JNK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.52 ± 0.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FGFR4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−1.53 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JNK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.16 ± 0.27</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AKT1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.48 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PLK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.19 ± 0.23</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AKT2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.38 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PAK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.32 ± 0.38</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Erk1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.72 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFRβ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−1.19 ± 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Erk2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.78 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RET</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−7.23 ± 0.29</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ROS1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−3.38 ± 0.26</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">WEE1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.76 ± 0.18</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0050" view="all">Results are expressed as means ± SD from three independent experiments.</ce:simple-para>
               </ce:legend>
            </ce:table>
         </ce:floats>
         <head>
            <ce:title id="title0010">Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523421002117-6607eb8df730e6782e3607e29706306b">
                  <ce:given-name>Xuebao</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0020" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523421002117-18a937bea0c8d7ed7cfeae6b05ac5a2b">
                  <ce:given-name>Kaiqi</ce:given-name>
                  <ce:surname>Wu</ce:surname>
                  <ce:cross-ref id="crosref0025" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0030" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523421002117-4ed0c0ae83bd3f216b3e31cfb37ff6c8">
                  <ce:given-name>Longcheng</ce:given-name>
                  <ce:surname>Fang</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0040" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523421002117-8eb60f99c61a478ebd02dfb15facfd0d">
                  <ce:given-name>Xiaojiao</ce:given-name>
                  <ce:surname>Yang</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523421002117-312458576e96b23c397c45e6404ea9e4">
                  <ce:given-name>Nan</ce:given-name>
                  <ce:surname>Zheng</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523421002117-37b4a37f1c9f698621fb0847ff815f8d">
                  <ce:given-name>Zongxuan</ce:given-name>
                  <ce:surname>Du</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523421002117-c7c577b4932565199bd18c3dda2527b6">
                  <ce:given-name>Ying</ce:given-name>
                  <ce:surname>Lu</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523421002117-633ebcaffcdeaa7d4b0432b52fad6473">
                  <ce:given-name>Zixin</ce:given-name>
                  <ce:surname>Xie</ce:surname>
                  <ce:cross-ref id="crosref0065" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523421002117-078f50b43502904980a19206401a8e79">
                  <ce:given-name>Zhiguo</ce:given-name>
                  <ce:surname>Liu</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au10" author-id="S0223523421002117-db126adde832fc85008ed7762d7ba3fe">
                  <ce:given-name>Zhigui</ce:given-name>
                  <ce:surname>Zuo</ce:surname>
                  <ce:cross-ref id="crosref0075" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0080" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au11" author-id="S0223523421002117-c80098e42f0c388b0a7e209213a6d463">
                  <ce:given-name>Faqing</ce:given-name>
                  <ce:surname>Ye</ce:surname>
                  <ce:cross-ref id="crosref0085" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0090" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0095" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523421002117-e9c8a17abc02348e576cd97a5d75ee4e">
                  <ce:label>a</ce:label>
                  <ce:textfn>Department of Colorectal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Colorectal Surgery</sa:organization>
                     <sa:organization>The First Affiliated Hospital of Wenzhou Medical University</sa:organization>
                     <sa:city>Wenzhou</sa:city>
                     <sa:state>Zhejiang</sa:state>
                     <sa:postal-code>325035</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Department of Colorectal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China, 325035</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523421002117-95a64ad634fa0d39d578fc6d00cfa0b0">
                  <ce:label>b</ce:label>
                  <ce:textfn>School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>School of Pharmaceutical Science</sa:organization>
                     <sa:organization>Wenzhou Medical University</sa:organization>
                     <sa:city>Wenzhou</sa:city>
                     <sa:state>Zhejiang</sa:state>
                     <sa:postal-code>325035</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, China, 325035</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author. Department of Colorectal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.</ce:text>
                  <sa:affiliation>
                     <sa:organization>Department of Colorectal Surgery</sa:organization>
                     <sa:organization>the First Affiliated Hospital of Wenzhou Medical University</sa:organization>
                     <sa:city>Wenzhou</sa:city>
                     <sa:state>Zhejiang</sa:state>
                     <sa:postal-code>325035</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contribute equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="6" month="12" year="2020"/></ce:date-received>
            <ce:date-revised day="22" month="2" year="2021"/></ce:date-revised>
            <ce:date-accepted day="27" month="2" year="2021"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Signal transducer and activator of transcription 3 (STAT3) has been confirmed as an attractive therapeutic target for cancer therapy. Herein, we designed and synthesized a series of N-substituted Sulfamoylbenzamide STAT3 inhibitors based on small-molecule STAT3 inhibitor Niclosamide. Compound B12, the best active compound of this series, was identified as an inhibitor of IL-6/STAT3 signaling with an IC<ce:inf loc="post">50</ce:inf> of 0.61–1.11 μM in MDA-MB-231, HCT-116 and SW480 tumor cell lines with STAT3 overexpression, by inhibiting the phosphorylation of STAT3 of Tyr705 residue and the expression of STAT3 downstream genes, inducing apoptosis and inhibiting the migration of cancer cells. Furthermore, in vivo study revealed that compound B12 suppressed the MDA-MB-231 xenograft tumor growth in nude mice at the dose of 30 mg/kg (i.g.), which has better antitumor activity than the positive control Niclosamide. More importantly, B12 is an orally bioavailable anticancer agent as a promising candidate for further development.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="ga1" xlink:href="pii:S0223523421002117/ga1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0020">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>N-substituted sulfamoylbenzamide STAT3 inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Niclosamide</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Anti-tumor activity</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:nomenclature id="nomen0010" view="all">
               <ce:section-title id="sectitle0025">Abbreviations used</ce:section-title>
               <ce:def-list id="dlist0010">
                  <ce:def-term id="d0010">IL-6</ce:def-term>
                  <ce:def-description id="defdis0010">
                     <ce:para id="p0010" view="all">interleukin-6</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0015">STAT3</ce:def-term>
                  <ce:def-description id="defdis0015">
                     <ce:para id="p0015" view="all">signal transduction and activators of transcription 3</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0020">RTK</ce:def-term>
                  <ce:def-description id="defdis0020">
                     <ce:para id="p0020" view="all">receptor tyrosine kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0025">MTT</ce:def-term>
                  <ce:def-description id="defdis0025">
                     <ce:para id="p0025" view="all">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0030">DMSO</ce:def-term>
                  <ce:def-description id="defdis0030">
                     <ce:para id="p0030" view="all">dimethyl sulfoxide</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0035">FBS</ce:def-term>
                  <ce:def-description id="defdis0035">
                     <ce:para id="p0035" view="all">fetal bovine serum</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0040">PBS</ce:def-term>
                  <ce:def-description id="defdis0040">
                     <ce:para id="p0040" view="all">phosphate belanced solution</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0045">WB</ce:def-term>
                  <ce:def-description id="defdis0045">
                     <ce:para id="p0045" view="all">western blot</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0050">PI</ce:def-term>
                  <ce:def-description id="defdis0050">
                     <ce:para id="p0050" view="all">propidium iodide</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0055">IC<ce:inf loc="post">50</ce:inf>
                  </ce:def-term>
                  <ce:def-description id="defdis0055">
                     <ce:para id="p0055" view="all">50% inhibiting concentration</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0060">TLC</ce:def-term>
                  <ce:def-description id="defdis0060">
                     <ce:para id="p0060" view="all">thin layer chromatography</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0065">
                     <ce:sup loc="post">1</ce:sup>HNMR</ce:def-term>
                  <ce:def-description id="defdis0065">
                     <ce:para id="p0065" view="all">nuclear Magnetic Resonance-<ce:sup loc="post">1</ce:sup>H</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0070">
                     <ce:sup loc="post">13</ce:sup>CNMR</ce:def-term>
                  <ce:def-description id="defdis0070">
                     <ce:para id="p0070" view="all">nuclear Magnetic Resonance-<ce:sup loc="post">13</ce:sup>C</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0075">CMC-Na</ce:def-term>
                  <ce:def-description id="defdis0075">
                     <ce:para id="p0075" view="all">carboxymethylcellulose-Na</ce:para>
                  </ce:def-description>
               </ce:def-list>
            </ce:nomenclature>
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0080" view="all">Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT protein family, which regulates cell growth, differentiation, apoptosis, angiogenesis and immune responses [<ce:cross-refs id="crosrefs0010" refid="bib1 bib2 bib3">1–3</ce:cross-refs>]. Abnormally activated STAT3 signaling is closely related to the occurrence and development of various malignant tumors (about 70% of human solid tumors and hematological tumors) [<ce:cross-refs id="crosrefs0015" refid="bib4 bib5 bib6 bib7 bib8">4–8</ce:cross-refs>]. In terms of STAT3 functional structure, it is mainly composed of six important domains: (1) N-terminal domain; (2) Coil-coil domain (CCD); (3) DNA binding domain (DBD); (4) linker domain; (5) SH2/TAD domain; (6) C-terminal domain [<ce:cross-refs id="crosrefs0020" refid="bib9 bib10 bib11">9–11</ce:cross-refs>]. STAT3 can be phosphorylated at Tyr705 on the SH2/TAD domain of STAT3 which is mediated by cytoplasmic kinases to form p-STAT3 monomer, which in turn forms a pSTAT3-pSTAT3 dimer with another monomeric p-STAT3. The dimerized STAT3 then translocates into the nucleus and binds to DNA, inducing gene transcription to exert biological activity [<ce:cross-ref id="crosref0100" refid="bib12">12</ce:cross-ref>,<ce:cross-ref id="crosref0105" refid="bib13">13</ce:cross-ref>]. Therefore, STAT3 is widely recognized as a key target in cancer therapy, and research on anti-tumor drugs targeting STAT3-related signaling pathways has also received much attention in recent years [<ce:cross-ref id="crosref0110" refid="bib14">14</ce:cross-ref>,<ce:cross-ref id="crosref0115" refid="bib15">15</ce:cross-ref>].</ce:para>
                  <ce:para id="p0085" view="all">Currently, the most common method to inhibit STAT3 is by blocking the upstream kinase to prevent STAT3 phosphorylation and activation (such as curcumin, resveratrol), or by interfering with the STAT3-SH2 domain to prevent the formation of STAT3 dimers (such as BP-1-102, S3I-201, Niclosamide, LY5, LLL12), thereby blocking this signaling [<ce:cross-ref id="crosref0120" refid="bib15">15</ce:cross-ref>,<ce:cross-ref id="crosref0125" refid="bib16">16</ce:cross-ref>]. These inhibitors have a certain effect, but they also have shortcomings, including: the lack of membrane permeability and stability, low hydrophobicity, weak binding affinity, or low specificity. So there are currently no STAT3-targeting inhibitor approved by the FDA to date. To discover and develop novel druggable STAT3 inhibitors with high potency remains promising and valuable.</ce:para>
                  <ce:para id="p0090" view="all">Niclosamide is an FDA-approved antihelminthic drug that has been used for several decades for its high efficiency and low toxicity [<ce:cross-refs id="crosrefs0025" refid="bib17 bib18 bib19">17–19</ce:cross-refs>]. With the development of drug repurposing initiatives, Niclosamide has become a true hit for screening many diseases, and also shows potential for cancer treatment [<ce:cross-refs id="crosrefs0030" refid="bib20 bib21 bib22">20–22</ce:cross-refs>]. Studies have shown that: (a) Niclosamide inhibits tumor cell proliferation and induces tumor cell apoptosis by inhibiting abnormal tumor signaling pathways such as mTOR, NF-KB, and STAT3; (b) due to the inhibitory effect of Niclosamide on STAT3 and other signaling pathways, it can be combined with traditional chemotherapy drugs to overcome drug resistance [<ce:cross-ref id="crosref0130" refid="bib23">23</ce:cross-ref>]; and (c) Niclosamide is used in combination with radiation therapy to overcome the radiation resistance of breast cancer and to act as a radiosensitizer [<ce:cross-ref id="crosref0135" refid="bib24">24</ce:cross-ref>]. Furthermore, Niclosamide is a STAT3 inhibitor screened from 1500 listed drugs by dual fluorescein reporter gene assay, which can selectively inhibit the phosphorylation of STAT3 and interfere with the STAT3 signaling pathway, thus playing a role against tumor cells. However, due to its poor hydrophobicity and low oral availability, the possibility of Niclosamide becoming an anti-tumor drug is limited [<ce:cross-ref id="crosref0140" refid="bib25">25</ce:cross-ref>]. Therefore, we used Niclosamide as a precursor for structural modification in order to improve its hydrophobicity while maintaining its activity in inhibiting STAT3 signaling pathway.</ce:para>
                  <ce:para id="p0095" view="all">By analyzing the structure of existing STAT3 inhibitors (<ce:cross-ref id="crosref0145" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>), it is not difficult to speculate that –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf>, which contains both hydrogen bond donor –NH– and hydrogen bond acceptor –SO<ce:inf loc="post">2</ce:inf>-, may be a key interacting group to enhance the ability to bind to STAT3, and that –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf> as a hydrophilic group can also improve the hydrophobicity of the compound. So we designed the compound NGT 02 derived from Niclosamide with –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf> (see <ce:cross-ref id="crosref0150" refid="sch1">Scheme 1</ce:cross-ref>
                     <ce:float-anchor refid="sch1"/></ce:float-anchor> for related design). Further studies found that although the antitumor activity of compound NGT 02 decreased (see <ce:cross-ref id="crosref0155" refid="tbl1a">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl1a"/></ce:float-anchor>a<ce:float-anchor refid="tbl1b"/></ce:float-anchor>), the hydrophobicity of NGT 02 was significantly improved (see <ce:cross-ref id="crosref0160" refid="tbl2">Table 2</ce:cross-ref>
                     <ce:float-anchor refid="tbl2"/></ce:float-anchor> logP). Therefore, we made further structural modifications of NGT 02. The activity of –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf> 
                     <ce:italic>ortho</ce:italic>-introduction chlorine was discussed, and the A and B series compounds were designed. According to the preliminary activity screening (see <ce:cross-ref id="crosref0165" refid="tbl1a">Table 1</ce:cross-ref>a), the compounds with good activity were modified by amide linker or further acylated against –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf> in order to obtain a more active compound, and thus compounds X, Y and Z series were designed.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and Discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0100" view="all">The synthetic route of the NGT 02 and compounds of A, B, X, Y, Z series were shown in <ce:cross-ref id="crosref0170" refid="sch2">Scheme 2</ce:cross-ref>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>. Intermediate NGT 01 was obtained by amidification of 2-chloro-4-nitroaniline with 2-methoxy-5-sulfamoylbenzoyl chloride obtained by chloration of the starting material 2-methoxy-5-sulfonamidobenzoic acid with dichlorosulfoxide, same as the synthesis method of intermediate NGT 01, compounds of A, B, X series was obtained by amidification of the substituted aromatic amine with 3-sulfonamidobenzoyl chloride or 4-chloro-3-sulfonamidobenzoyl chloride obtained by chloration of the starting material 3-sulfonamidobenzoic acid or 4-chloro-3-sulfonamidobenzoic acid with dichlorosulfoxide. Synthesis of NGT 02 from NGT 01 catalyzed by 5% Pd–C under H<ce:inf loc="post">2</ce:inf> conditions. The Y and Z series compounds were based on the reaction of the first three series of compounds with the corresponding substituted linear acid chloride or aromatic acid chloride.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Biological evaluation</ce:section-title>
                     <ce:section id="sec2.2.1" view="all">
                        <ce:label>2.2.1</ce:label>
                        <ce:section-title id="sectitle0050">Cell viability assay and SAR analysis</ce:section-title>
                        <ce:para id="p0105" view="all">Initially, four cell lines (three STAT3 high-expressing cell lines (MDA-MB-231, HCT-116, SW480) and one non-STAT3 high-expressing cell line (L3.6)) were used to screen the inhibitory rate of all the synthesized compounds (<ce:cross-ref id="crosref0175" refid="tbl1a">Table 1</ce:cross-ref>a, <ce:cross-ref id="crosref0180" refid="tbl1b">Table 1</ce:cross-ref>b). The results showed that the inhibitory effect of the synthesized compounds on STAT3 high expression cell lines was generally better than that of non-STAT3 high expression cell lines, which indicated that the compounds we designed have selectivity for STAT3. Among them, the compounds B6 and B12 performed best. However, the anti-tumor effects of the Y and Z series compounds obtained by further acylation of –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf> were generally inferior to those of other series of compounds. This suggest the necessity of –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf> for activity. Then, IC<ce:inf loc="post">50</ce:inf> value for the compounds, which the inhibition rate of all three cells was more than 50%, were tested by MTT assays, and Niclosamide was used as a positive control. The most potent compound B12 inhibited the growth of MDA-MB-231, HCT-116, SW480 cells with IC<ce:inf loc="post">50</ce:inf> values of 0.61, 0.79, 1.11 μM showed that it has a good inhibitory effect on these three tumor cells and slightly better than Niclosamide (<ce:cross-ref id="crosref0185" refid="tbl2">Table 2</ce:cross-ref>).</ce:para>
                        <ce:para id="p0110" view="all">LogP is a measure of the hydrophobicity of the compound. We tested the logP values of the synthesized compound and the positive control to determine whether the modified compound has improved hydrophobicity compared to the positive control. <ce:cross-ref id="crosref0190" refid="tbl2">Table 2</ce:cross-ref> listed the logP values of some active compounds and Niclosamide. It can be seen that the designed compounds are less hydrophobic than the positive control, that is, the hydrophobicity is improved, including the most potent compound B12.</ce:para>
                        <ce:para id="p0115" view="all">SAR analysis showed that: (1) According to the logP results, replacing the 5-position Cl of Niclosamide with –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf> can significantly improve the bioavailability but decrease hydrophobicity of the compound (<ce:cross-ref id="crosref0195" refid="tbl2">Table 2</ce:cross-ref>). (2) The removal of 2-position-OH not only simplifies the synthesis of the compound but also preserves the anti-proliferative activity of the compound (like NGT02 vs A10 in <ce:cross-ref id="crosref0200" refid="tbl1a">Table 1</ce:cross-ref>a); (3) The structure of N-substituted sulfamoylbenzamide derivatives further acylated of the –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf> group can greatly decrease the biological activity (like B6 vs Y, Z series), this result also indicates the importance of the –SO<ce:inf loc="post">2</ce:inf>NH<ce:inf loc="post">2</ce:inf> group for the anti-proliferative activity of STAT3 overexpressing tumor cells. (4) The introduction of a chlorine atom at the 4-position of the benzene ring of the compound generally enhances the inhibitory activity of the compound on the above-mentioned cancer cells (like B6 vs A6; A13 vs B12); So, chlorine atoms remain unchanged in the subsequent modification; (5) The carbon chain elongation linked to benzsulfonamide N can sometimes decrease the anti-proliferative activity of the compounds (like X5 vs B6).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.2" view="all">
                        <ce:label>2.2.2</ce:label>
                        <ce:section-title id="sectitle0055">Inhibitory effect of STAT3 tyrosine phosphorylation</ce:section-title>
                        <ce:para id="p0120" view="all">The ability of three dominant compounds (A13, B6, B12) to inhibit the phosphorylation of STAT3 was determined in MDA-MB-231 cells (<ce:cross-ref id="crosref0205" refid="tbl3">Table 3</ce:cross-ref>
                           <ce:float-anchor refid="tbl3"/></ce:float-anchor>). B12, which exhibits the most potent anti-proliferative activity, inhibits the phosphorylation of STAT3 with an IC50 value of 0.23 μM. And its inhibition is comparable to Niclosamide. Compound A13 which does not introduce a chlorine atom at the 4-position of the compound benzene ring has a weaker inhibitory effect on STAT3 kinase phosphorylation than the compound B6 and B12. This result further confirms that the introduction of chlorine atoms at the 4-position of the benzene ring of the compound increases the selectivity of compounds for STAT3. We also conducted Western blot analysis to confirm the inhibitory activity of B12 on STAT3 phosphorylation. It was showed that B12 markedly suppressed STAT3 phosphorylation at Tyr705 residue in a dose-dependent manner with the expression of total STAT3 not changed, which indicated that the decrease of p-STAT3 (Y705) has no concern with a constitutional decrease of total STAT3 expression (<ce:cross-ref id="crosref0210" refid="fig2">Fig. 2</ce:cross-ref>
                           <ce:float-anchor refid="fig2"/></ce:float-anchor>A). STAT3 can be induced by IL-6. We can clearly know that B12 significantly inhibited STAT3 phosphorylation elevated by IL-6. And compound B12 almost completely blocked the stimulation at 5 μM (<ce:cross-ref id="crosref0215" refid="fig2">Fig. 2</ce:cross-ref>B). These results was consistent with <ce:cross-ref id="crosref0220" refid="tbl2">Table 2</ce:cross-ref>.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.3" view="all">
                        <ce:label>2.2.3</ce:label>
                        <ce:section-title id="sectitle0060">The selectivity of compound B12 to STAT3</ce:section-title>
                        <ce:para id="p0125" view="all">STAT1 and STAT3 are structurally homologous, but STAT1 plays a role in inhibiting tumor cell proliferation and promoting apoptosis of tumor cells [<ce:cross-ref id="crosref0225" refid="bib26">26</ce:cross-ref>]. Thus, in the design of STAT3 small molecule inhibitors, the selectivity of STAT1 should be detected [<ce:cross-ref id="crosref0230" refid="bib27">27</ce:cross-ref>]. So Western blot assays were performed to investigate the effects of B12 on STAT1 phosphorylation. As shown in <ce:cross-ref id="crosref0235" refid="fig3">Fig. 3</ce:cross-ref>
                           <ce:float-anchor refid="fig3"/></ce:float-anchor>, B12 had little influence on the extent of STAT1 phosphorylation.</ce:para>
                        <ce:para id="p0130" view="all">After that, we tested 34 kinases associated with antitumor to further verify the selectivity of B12 with10 μM. Some of these activated kinases could promote the activation of STAT3 directly or indirectly. The results were shown in <ce:cross-ref id="crosref0240" refid="tbl4">Table 4</ce:cross-ref>
                           <ce:float-anchor refid="tbl4"/></ce:float-anchor>. The maximum inhibition rate of B12 on these kinases was only 9.32%. To a certain extent, compound B12 can selectively inhibit STAT3 phosphorylation.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.4" view="all">
                        <ce:label>2.2.4</ce:label>
                        <ce:section-title id="sectitle0065">Compound B12 could inhibit promoter activity of STAT3</ce:section-title>
                        <ce:para id="p0135" view="all">STAT3 promoter activity was examined in MDA-MB-231 cells transiently transfected with pSTAT3-Luc vector using dual luciferase reporter assay. The STAT3 promoter activity were decreased by 24.7%, 80.6% and 87.9%, in the cells treated with B12 at concentrations of 0.1, 0.5 and 1.0 μM, respectively (<ce:cross-ref id="crosref0245" refid="fig4">Fig. 4</ce:cross-ref>
                           <ce:float-anchor refid="fig4"/></ce:float-anchor>). In other words, the inhibition was in a dose-dependent manner. In MDA-MB-231 cells, B12 has an inhibit promoter activity of STAT3 comparable to that of Niclosamide (decreased by 88.2% at concentrations of 1.0 μM).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.5" view="all">
                        <ce:label>2.2.5</ce:label>
                        <ce:section-title id="sectitle0070">Compound B12 induced apoptosis and caused changes in related apoptotic proteins</ce:section-title>
                        <ce:para id="p0140" view="all">We had demonstrated that compound B12 can effectively inhibit STAT3 activation. To further explore the mechanism of B12 in this pathway, we examined its effect on the related apoptotic proteins. MDA-MB-231 cells were treated with compound B12 and detected by Western blot. As can be seen from <ce:cross-ref id="crosref0250" refid="fig5">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>, the compound B12 inhibited the expression of the Anti-apoptotic protein, Bcl-xl and induced apoptosis proteins such as Cleaved-PARP, Cleaved-caspase 9, and Cleaved-caspase 3.</ce:para>
                        <ce:para id="p0145" view="all">We also analyzed the effect of compound B12 on the induction of tumor cell apoptosis. MDA-MB-231 cells were treated with B12 at different concentrations for 24 h. Annexin V-FITC/PI staining was performed and the percentages of apoptotic cells were further determined using flow cytometry. As shown in <ce:cross-ref id="crosref0255" refid="fig6">Fig. 6</ce:cross-ref>
                           <ce:float-anchor refid="fig6"/></ce:float-anchor>, B12 significantly induced apoptosis in MDA-MB-231 cells in a dose-dependent manner. In summary, compound B12 induced the apoptosis of tumor cells through activating the caspase-dependent pathway relating to Bcl-xl, which was regulated by the deactivation of STAT3 protein.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.6" view="all">
                        <ce:label>2.2.6</ce:label>
                        <ce:section-title id="sectitle0075">Compound B12 reduced tumor cells colony formation in vitro</ce:section-title>
                        <ce:para id="p0150" view="all">We used colony formation assays to further assess the in vitro anti-proliferative capacity of B12. After treatment with different concentrations of B12 for 24 h, MDA-MB-231 cells were replaced with fresh medium without B12 for 14 days until the colonies were visible. As shown in <ce:cross-ref id="crosref0260" refid="fig7">Fig. 7</ce:cross-ref>
                           <ce:float-anchor refid="fig7"/></ce:float-anchor>, B12 significantly inhibited the formation of colonies at 1 μM, and the inhibitory effect was comparable to that of the positive control.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.7" view="all">
                        <ce:label>2.2.7</ce:label>
                        <ce:section-title id="sectitle0080">Compound B12 inhibited migration of cancer cells in vitro</ce:section-title>
                        <ce:para id="p0155" view="all">Overexpression of STAT3 is closely linked with the migration of tumor cells. Therefore, the effects of B12 on cell migration of MDA-MB-231 cells were further assessed by transwell assay. MDA-MB-231 cells were plated in the upper chamber containing a membrane, then cells were treated with B12 or Niclosamide for 24 h, and cells on the underside of the membrane was imaged under light microscopy. The results showed that migration of MDA-MB-231 cells was inhibited in a dose-dependent manner when treated with B12 (<ce:cross-ref id="crosref0265" refid="fig8">Fig. 8</ce:cross-ref>
                           <ce:float-anchor refid="fig8"/></ce:float-anchor>). Meanwhile, at the same concentration (1000 nM), the inhibition of tumor cell migration in the group of administration B12 has the same effect, compared with Niclosamide.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.8" view="all">
                        <ce:label>2.2.8</ce:label>
                        <ce:section-title id="sectitle0085">Compound B12 inhibited tumor growth in a mouse breast cancer model</ce:section-title>
                        <ce:para id="p0160" view="all">To further evaluated the inhibitory effect of B12 on breast cancer xenografts in vivo, and tumor volume was measured. After the solid tumor was established, fifteen nude mice were randomly divided into three groups, which were blank control group, B12 administration group and Niclosamide administration group by intragastric gavage. As we could see from the results (<ce:cross-ref id="crosref0270" refid="fig9">Fig. 9</ce:cross-ref>
                           <ce:float-anchor refid="fig9"/></ce:float-anchor>), B12 could significantly inhibit tumor growth. and the ability of B12 to inhibit tumor growth was comparable to that of the positive control (<ce:cross-ref id="crosref0275" refid="fig9">Fig. 9</ce:cross-ref>B and <ce:cross-ref id="crosref0280" refid="fig9">D</ce:cross-ref>). Moreover, perhaps the increase in hydrophilicity improves the bioavailability of B12, resulting B12 being better than the positive control in inhibiting tumor growth, and the results were statistically significant. At the same time, during the administration period, the weight of nude mice did not increase or decrease significantly.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0090">Conclusions</ce:section-title>
                  <ce:para id="p0165" view="all">Taken together, the query was verified that Niclosamide-modified sulfonamide derivative B12 can improve hydrophobicity and maintain its activity in inhibiting STAT3 signaling pathway. The first reported 52 compounds including A13, B6 and B12 were designed, synthesized and evaluated for their bioactivity. Among all synthesized compounds, compounds A13, B6 and B12 exhibited biological activities equivalent to or even superior to the lead compound Niclosamide; The Western blot assays, kinase activity assays, STAT3 ELISA kit and STAT3 promoter activity studies indicated that B12 could inhibit STAT3 phosphorylation. Additionally, cell apoptosis assays demonstrated that B12 could promote apoptosis of cancer cells; Transwell assays showed that B12 could be able to inhibit the migration of MDA-MB231 cells; In addition, B12 can inhibit the formation of tumor cell colonies. Importantly, B12 showed the better anti-tumor effects than Niclosamide in vivo though a MDA-MB-231-driven xenograft mouse model. These results have demonstrated that B12 is worthy of further research to develop as novel small-molecule STAT3 inhibitor for human cancer.</ce:para>
               </ce:section>
               <ce:section id="sec4" role="materials-methods" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0095">Materials and methods</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0100">Chemistry</ce:section-title>
                     <ce:para id="p0170" view="all">All materials and reagents were purchased from commercial suppliers and used without further purification unless otherwise stated. The progress of the reaction was monitored by analytical thin layer chromatography (TLC) using a silica gel GF254 plate (Qingdao Haiyang Chemical Plant, China), and the spots were observed under UV light of 254 nm or 365 nm. Column chromatography was carried out on silica gel (90–150 μM; Qingdao Ocean Chemical Co., Ltd.). The melting point measured on the XT-4 micromelting point apparatus without corrected. <ce:sup loc="post">1</ce:sup>H NMR and <ce:sup loc="post">13</ce:sup>C NMR spectra were measured on a Bruker 600 MHz Avanve NMR spectrometer or a Bruker 500 MHz Avanve NMR spectrometer using CDCl<ce:inf loc="post">3</ce:inf> or DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> as a solvent. Mass spectra were obtained on an ACQUITY I-Class UPLC and a XEVO TQD triple quadrupole Mass Spectrometer (Waters Corp., Milford, USA). HPLC (Agilent 1260，USA) was used to detect the purity of the compounds, and the results showed that all of them exceeded 96%. Elemental analysis for C, H and N were analyzed using elemental analyser (Flash EA1112) and were found within ±0.5% of the theoretical values.</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0105">Synthetic routes of N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-sulfamoylbenzamide (NGT 02)</ce:section-title>
                        <ce:para id="p0175" view="all">
                           <ce:list id="olist0010">
                              <ce:list-item id="o0010">
                                 <ce:label>a.</ce:label>
                                 <ce:para id="p0180" view="all">2-methoxy-5-sulfonamidobenzoic acid (1 g, 4.3 mmol) and 30 mL of freshly steamed SOCl<ce:inf loc="post">2</ce:inf> were refluxed at 105 °C for 3–5 h. The mixture was allowed to stand for cooling, and the thionyl chloride was concentrated under reduced pressure to give 2-methoxy-5sulfonamidobenzoyl chloride;</ce:para>
                              </ce:list-item>
                              <ce:list-item id="o0015">
                                 <ce:label>b.</ce:label>
                                 <ce:para id="p0185" view="all">The raw material 2-chloro-4-nitroaniline (460 mg, 2.7 mmol) was weighed and dissolved in 20 mL of dichloromethane, and 350 μL of the base N,N-diisopropylethylamine (DIPEA, 2.7 mmol) was added.), stirring in ice bath for 15 min. Then, 4 mmol of the above-obtained 2-methoxy-5-sulfonamidobenzoyl chloride was added, and the mixture was stirred for 12 h under ice-cooling, and the reaction was monitored by the TLC method. After the reaction is terminated, the product is isolated and purified to obtain the intermediate N-(2-chloro-4-nitrophenyl)-2-methoxy-5-sulfonamidobenzamide (NGT 01);</ce:para>
                              </ce:list-item>
                              <ce:list-item id="o0020">
                                 <ce:label>c.</ce:label>
                                 <ce:para id="p0190" view="all">The intermediate NGT 01 (110 mg, 0.28 mmol) and 5% pd/C catalyst (14 mg) were dissolved in 10 mL of ethyl acetate:ethanol (1:1) in H<ce:inf loc="post">2</ce:inf> at room temperature. The reaction was carried out for 8 h, and the progress of the reaction was monitored by the TLC method. After the reaction was terminated, the mixture was concentrated under reduced pressure, and then purified by column chromatography to give the product N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-sulfonamidobenzamide (NGT 02).</ce:para>
                              </ce:list-item>
                           </ce:list>
                        </ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0110">Synthetic routes of compound a series, B series and X series</ce:section-title>
                        <ce:para id="p0195" view="all">
                           <ce:list id="olist0015">
                              <ce:list-item id="o0025">
                                 <ce:label>a.</ce:label>
                                 <ce:para id="p0200" view="all">3-sulfonamidobenzoic acid or 4-chloro-3-sulfonamidobenzoic acid (3 mmol) and 30 mL of freshly steamed SOCl<ce:inf loc="post">2</ce:inf>, were refluxed at 105 °C for 3–5 h. Cooling and standing, then evaporating the thionyl chloride under reduced pressure to obtain 3-sulfonyl benzoyl chloride or 4-chloro-3-sulfonyl benzoyl chloride;</ce:para>
                              </ce:list-item>
                              <ce:list-item id="o0030">
                                 <ce:label>b.</ce:label>
                                 <ce:para id="p0205" view="all">The corresponding substituted aromatic amine (0.5 mmol) was weighed and dissolved in 10 mL of dichloromethane, and 65 μL of base DIPEA (0.5 mmol) was added, and the mixture was stirred for 15 min in an ice bath. Then, 0.75 mmol of the above-obtained 3-sulfonamidobenzoyl chloride or 4-chloro-3-sulfonamidobenzoyl chloride was added, and the mixture was stirred for 12 h under ice-cooling, and the reaction was monitored by TLC. After the reaction is terminated, the product is isolated and purified to obtain three series of compounds: A, B and X.</ce:para>
                              </ce:list-item>
                           </ce:list>
                        </ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0115">Synthetic routes of compound Y series and Z series</ce:section-title>
                        <ce:para id="p0210" view="all">4-chloro-3-sulfamoyl-N-(3,4,5-trimethoxyphenyl)benzamide (100 mg, 0.25 mmol), NaH (24 mg, 1 mmol), were dissolved in 5 mL of anhydrous tetrahydrofuran and refluxed at room temperature for 30 min with Nitrogen protection. Then, the corresponding substituted linear acid chloride or aromatic acid chloride dissolved in 5 mL of anhydrous tetrahydrofuran was added, and the mixture was stirred at room temperature for 12 h, and the progress of the reaction was monitored by TLC. After the reaction is terminated, the product is isolated and purified to obtain three series of compounds: Y and Z.</ce:para>
                        <ce:para id="p0215" view="all">
                           <ce:italic>N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-sulfamoylbenzamide (NGT 02).</ce:italic> Yield/%: 25.2%; MP: 199.2–201.3 °C; ESI-MS: 372.22 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 12.54 (s, 1H, 2-OH), 10.73 (s, 1H), 8.58 (d, 1H, <ce:italic>J</ce:italic> = 2.0 Hz), 8.45 (d, 1H, <ce:italic>J</ce:italic> = 2.5 Hz), 8.29 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.5 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.0 Hz), 8.22 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.0 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.0 Hz), 8.01 (d, 1H, <ce:italic>J</ce:italic> = 7.0 Hz), 7.89 (d, 1H, <ce:italic>J</ce:italic> = 7.0 Hz), 7.80 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 162.2, 159.8, 142.8, 140.9, 137.2, 131.8, 129.5, 124.7, 123.8, 122.9, 121.0, 120.4, 113.5. Anal. Calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">10</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">6</ce:inf>S: C, 41.96; H, 2.72; N, 11.30. Found: C, 41.89; H, 2.71; N, 11.26.</ce:para>
                        <ce:para id="p0220" view="all">
                           <ce:italic>N-(2-methoxyphenyl)-3-sulfamoylbenzamide (A1).</ce:italic> Yield/%: 83.5%; MP: 183.6–186.1 °C; ESI-MS: 307.11 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.78 (s, 1H), 8.39 (s, 1H), 8.18 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.01 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.73 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.68 (t, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.51 (s, 2H), 7.21 (m, 1H), 7.11 (d, 1H, <ce:italic>J</ce:italic> = 7.8Hz), 6.97 (m, 1H), 3.83 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.0, 151.9, 144.5, 135.3, 130.4, 129.3, 128.4, 126.5, 126.2, 125.1, 124.9, 120.2, 111.6, 55.7. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">14</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 54.84; H, 4.57; N, 9.14. Found: C, 54.78; H, 4.58; N, 9.13.</ce:para>
                        <ce:para id="p0225" view="all">
                           <ce:italic>N-(3-methoxyphenyl)-3-sulfamoylbenzamide (A2).</ce:italic> Yield/%: 85.7%; MP: 182.8–185.0 °C; ESI-MS: 307.05 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.48 (s, 1H), 8.38 (s, 1H), 8.17 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.02 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.75 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.51 (s, 2H), 7.46 (t, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 7.38 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.28 (t, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 6.72 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 3.76 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 165.0, 160.0, 145.1, 140.6, 136.2, 131.3, 130.1, 129.8, 129.1, 125.7, 113.3, 110.1, 106.8, 55.6. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">14</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 54.84; H, 4.57; N, 9.14. Found: C, 54.85; H, 4.56; N, 9.15.</ce:para>
                        <ce:para id="p0230" view="all">
                           <ce:italic>N-(4-methoxyphenyl)-3-sulfamoylbenzamide (A3).</ce:italic> Yield/%: 88.9%; MP: 179.3–182.4 °C; ESI-MS: 306.98 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.38 (s, 1H), 8.38 (s, 1H), 8.17 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.01 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.73 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.67 (d, 2H, <ce:italic>J</ce:italic> = 9.0 Hz), 7.48 (s, 2H), 6.95 (d, 2H, <ce:italic>J</ce:italic> = 9.0 Hz), 3.75 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.5, 156.4, 145.0, 136.3, 132.5, 131.2, 129.8, 128.9, 125.6, 122.7, 114.4, 55.8. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">14</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 54.84; H, 4.57; N, 9.14. Found: C, 54.76; H, 4.57; N, 9.14.</ce:para>
                        <ce:para id="p0235" view="all">
                           <ce:italic>N-(3, 5-dimethoxyphenyl)-3-sulfamoylbenzamide (A4).</ce:italic> Yield/%: 87.6%; MP: 187.1–190.3 °C; ESI-MS: 337.07 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.43 (s, 1H), 8.37 (s, 1H), 8.16 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.02 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.74 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.51 (s, 2H), 7.08 (d, 2H, <ce:italic>J</ce:italic> = 2.4 Hz), 6.30 (t, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 3.74 (s, 6H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 165.0, 161.0, 145.1, 141.1, 136.2, 131.3, 129.8, 129.1, 125.7, 99.3, 96.6, 55.8. Anal. Calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">16</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">5</ce:inf>S: C, 53.51; H, 4.80; N, 8.32. Found: C, 53.50; H, 4.79; N, 8.35.</ce:para>
                        <ce:para id="p0240" view="all">
                           <ce:italic>N-(2, 5-dimethoxyphenyl)-3-sulfamoylbenzamide (A5).</ce:italic> Yield/%: 81.9%; MP: 189.3–191.0 °C; ESI-MS: 337.13 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.70 (s, 1H), 8.38 (s, 1H), 8.16 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 8.01 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.73 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.49 (s, 2H), 7.43 (d, 1H, <ce:italic>J</ce:italic> = 3.0 Hz), 7.03 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz), 6.77 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 9.0 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 3.0 Hz), 3.79 (s, 3H), 3.72 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.6, 153.4, 146.4, 145.1, 135.8, 131.1, 129.9, 129.1, 127.9, 125.7, 112.9, 111.5, 110.7, 56.8, 56.1. Anal. Calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">16</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">5</ce:inf>S: C, 53.51; H, 4.80; N, 8.32. Found: C, 53.47; H, 4.80; N, 8.33.</ce:para>
                        <ce:para id="p0245" view="all">
                           <ce:italic>3-sulfamoyl-N-(3, 4, 5-trimethoxyphenyl)benzamide (A6).</ce:italic> Yield/%: 84.6%; MP: 243.3–246.1 °C; ESI-MS: 367.09 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.42 (s, 1H), 8.39 (s, 1H), 8.17 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.02 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.75 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.51 (s, 2H), 7.22 (s, 2H), 3.78 (s, 6H), 3.64 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.8, 153.2, 145.1, 136.2, 135.6, 134.5, 131.2, 129.8, 129.1, 125.6, 98.8, 60.7, 56.4. Anal. Calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">6</ce:inf>S: C, 52.40; H, 4.96; N, 7.64. Found: C, 53.46; H, 4.94; N, 7.63.</ce:para>
                        <ce:para id="p0250" view="all">
                           <ce:italic>3-sulfamoyl-N-(2-(trifluoromethyl)phenyl)benzamide (A7).</ce:italic> Yield/%: 92.3%; MP: 174.9–177.2 °C; ESI-MS: 345.07 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.46 (s, 1H), 8.39 (s, 1H), 8.17 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.04 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.83 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.77 (td, 2H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.2 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.53 (m, 4H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 165.3, 144.6, 135.5, 134.6, 133.2, 131.2, 130.5, 129.3, 128.7, 127.7, 126.6, 125.1, 124.7, 122.5. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 48.79; H, 3.23; N, 8.13. Found: C, 48.71; H, 3.22; N, 8.11.</ce:para>
                        <ce:para id="p0255" view="all">
                           <ce:italic>3-sulfamoyl-N-(3-(trifluoromethyl)phenyl)benzamide (A8).</ce:italic> Yield/%: 98.6%; MP: 172.3–174.2 °C; ESI-MS: 345.13 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.81 (s, 1H), 8.41 (s, 1H), 8.23 (s, 1H), 8.21 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.04 (m, 2H), 7.78 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.63 (t, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.53 (s, 2H), 7.49 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 165.4, 145.2, 140.3, 135.7, 131.4, 130.6, 130.1, 130.0, 129.9, 129.4, 125.7, 124.6, 120.9, 117.1. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 48.79; H, 3.23; N, 8.13. Found: C, 48.78; H, 3.24; N, 8.14.</ce:para>
                        <ce:para id="p0260" view="all">
                           <ce:italic>3-sulfamoyl-N-(4-(trifluoromethyl)phenyl)benzamide (A9).</ce:italic> Yield/%: 95.6%; MP: 171.3–174.6 °C; ESI-MS: 345.01 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.81 (br-s, 1H), 8.40 (s, 1H), 8.20 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.05 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.02 (d, 2H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.75 (m, 3H), 7.53 (br-s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 165.5, 145.2, 143.1, 135.8, 131.5, 129.9, 129.4, 126.6, 125.8, 124.6, 124.4, 120.9. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 48.79; H, 3.23; N, 8.13. Found: C, 48.77; H, 3.24; N, 8.14.</ce:para>
                        <ce:para id="p0265" view="all">
                           <ce:italic>N-(2-chloro-4-nitrophenyl)-3-sulfamoylbenzamide (A10).</ce:italic> Yield/%: 29.6%; MP: 238.3–239.1 °C; ESI-MS: 355.95 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.68 (s, 1H), 8.43 (m, 2H), 8.29 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 9.0 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 8.22 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.08 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 8.01 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.79 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.55 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 165.2, 145.6, 145.3, 141.8, 134.7, 131.6, 130.1, 129.8, 129.4, 128.0, 126.0, 125.6, 123.6. Anal. Calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">10</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S: C, 43.85; H, 2.84; N, 11.81. Found: C, 43.86; H, 2.84; N, 11.83.</ce:para>
                        <ce:para id="p0270" view="all">
                           <ce:italic>N-(pyridin-</ce:italic>3-yl<ce:italic>)-3-sulfamoylbenzamide (A11).</ce:italic> Yield/%: 21.9%; MP: 188.2–191.8 °C; ESI-MS: 278.05 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.71 (s, 1H), 8.93 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.41 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.34 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 4.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.2 Hz), 8.19 (m, 2H), 8.05 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.77 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.51 (s, 2H), 7.41 (m, 1H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.8, 144.8, 144.6, 142.1, 135.5, 135.0, 130.7, 129.3, 128.7, 127.5, 125.1, 123.5. Anal. Calcd for. C<ce:inf loc="post">12</ce:inf>H<ce:inf loc="post">11</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 51.98; H, 4.00; N, 15.15. Found: C, 51.94; H, 4.01; N, 15.13.</ce:para>
                        <ce:para id="p0275" view="all">
                           <ce:italic>4, 5-dimethoxy-2-(3-sulfamoylbenzamido)benzoic acid (A12).</ce:italic> Yield/%: 49.6%; MP: 273.3–275.2 °C; ESI-MS: 381.11 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 13.67 (br-s, 1H), 12.42 (s, 1H), 8.46 (s, 1H), 8.43 (s, 1H), 8.14 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.07 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.81 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.54 (s, 2H), 7.50 (s, 1H), 3.88 (s, 3H), 3.79 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 170.5, 163.8, 153.9, 145.6, 144.6, 137.1, 135.8, 130.6, 130.5, 129.6, 125.0, 113.4, 108.7, 104.0, 56.2. Anal. Calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">16</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 50.48; H, 4.25; N, 7.36. Found: C, 50.39; H, 4.25; N, 7.38.</ce:para>
                        <ce:para id="p0280" view="all">
                           <ce:italic>4, 5-dimethoxy-2-(3-sulfamoylbenzamido)benzoic acid (A13).</ce:italic> Yield/%: 84.3%; MP: 282.3–284.2 °C; ESI-MS: 377.24 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.79 (s, 1H), 8.41 (s, 1H), 8.21 (d, 1H, <ce:italic>J</ce:italic> = 7.5 Hz), 8.05 (d, 1H, <ce:italic>J</ce:italic> = 7.5 Hz), 7.93 (m, 4H), 7.77 (t, 1H, <ce:italic>J</ce:italic> = 7.5 Hz), 7.50 (s, 2H), 1.56 (s, 9H); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.8, 164.6, 144.5, 143.0, 135.3, 130.8, 129.9, 129.2, 128.7, 126.4, 125.2, 119.7, 80.4, 27.8. Anal. Calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">20</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">5</ce:inf>S: C, 57.38; H, 5.37; N, 7.44. Found: C, 57.27; H, 5.38; N, 7.45.</ce:para>
                        <ce:para id="p0285" view="all">
                           <ce:italic>4-chloro-N-(2-methoxyphenyl)-3-sulfamoylbenzamide (B1).</ce:italic> Yield/%: 78.3%; MP: 204.3–206.5 °C; ESI-MS: 341.00 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.82 (s, 1H), 8.50 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.14 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.79 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.73 (s, 2H), 7.65 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.19 (m, 1H), 7.09 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 6.96 (t, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 3.81 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.9, 152.7, 141., 134.1, 134.1, 132.4, 132.3, 129.1, 127.0, 126.9, 125.8, 120.8, 112.2, 56.3. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">13</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 49.30; H, 3.85; N, 8.22. Found: C, 49.21; H, 3.84; N, 8.19.</ce:para>
                        <ce:para id="p0290" view="all">
                           <ce:italic>4-chloro-N-(3-methoxyphenyl)-3-sulfamoylbenzamide (B2).</ce:italic> Yield/%: 30.5%; MP: 206.3–209.8 °C; ESI-MS: 341.06 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.48 (s, 1H), 8.50 (s, 1H), 8.15 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.81 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.73 (s, 2H), 7.42 (s, 1H), 7.34 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.26 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 6.70 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 3.74 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.2, 160.0, 141.8, 140.5, 134.4, 134.1, 132.6, 132.3, 130.1, 129.1, 113.3, 110.2, 106.9, 55.7. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">13</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 49.30; H, 3.85; N, 8.22. Found: C, 49.28; H, 3.85; N, 8.20.</ce:para>
                        <ce:para id="p0295" view="all">
                           <ce:italic>4-chloro-N-(4-methoxyphenyl)-3-sulfamoylbenzamide (B3).</ce:italic> Yield/%: 20.4%; MP: 202.2–204.6 °C; ESI-MS: 341.06 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.57 (s, 1H), 8.57 (m, 1H), 8.20 (m, 1H), 7.77 (dd, 2H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.70 (m, 3H), 6.92 (d, 2H, <ce:italic>J</ce:italic> = 8.4 Hz), 3.73 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.9, 152.7, 141.8, 134.1, 132.3, 129.1, 127.0, 126.9, 125.8, 120.8, 112.2, 56.3. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">13</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 49.30; H, 3.85; N, 8.22. Found: C, 49.23; H, 3.85; N, 8.23.</ce:para>
                        <ce:para id="p0300" view="all">
                           <ce:italic>4-chloro-N-(3,5-dimethoxyphenyl)-3-sulfamoylbenzamide (B4).</ce:italic> Yield/%: 26.1%; MP: 197.2–199.1 °C; ESI-MS: 371.08 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.43 (s, 1H), 8.48 (d, 1H, <ce:italic>J</ce:italic> = 1.2Hz), 8.14 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.81 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.74 (s, 2H), 7.03 (d, 2H, <ce:italic>J</ce:italic> = 1.8 Hz), 6.28 (s, 1H), 3.7 (s, 6H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.2, 161.0, 141.8, 141.0, 134.4, 134.2, 132.5, 132.3, 129.1, 99.3, 96.7, 55.9, 55.8. Anal. Calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">15</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">5</ce:inf>S: C, 48.54; H, 4.09; N, 7.50. Found: C, 48.37; H, 4.10; N, 7.51.</ce:para>
                        <ce:para id="p0305" view="all">
                           <ce:italic>4-chloro-N-(2,5-dimethoxyphenyl)-3-sulfamoylbenzamide (B5).</ce:italic> Yield/%: 13.0%; MP: 199.3–201.1 °C; ESI-MS: 371.08 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.77 (s, 1H), 8.48 (s, 1H), 8.12 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.79 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.74 (s, 2H), 7.38 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.01 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 6.76 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 9.0 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 3.0 Hz), 3.76 (s, 3H) 3.70 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.9, 153.4, 146.5, 141.8, 134.1, 134.1, 132.4, 132.3, 129.1, 127.7, 112.9, 111.6, 110.9, 56.8, 56.1. Anal. Calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">15</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">5</ce:inf>S: C, 48.54; H, 4.09; N, 7.55. Found: C, 48.45; H, 4.09; N, 7.58.</ce:para>
                        <ce:para id="p0310" view="all">
                           <ce:italic>4-chloro-3-sulfamoyl-N-(3,4,5-trimethoxyphenyl)benzamide (B6).</ce:italic> Yield/%: 88.7%; MP: 254.3–256.4 °C; ESI-MS: 401.06 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.43 (s, 1H), 8.53 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.17 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.84 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.75 (s, 2H), 7.20 (s, 2H), 3.78 (s, 6H), 3.65 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.9, 153.2, 141.8, 135.4, 134.6, 134.4, 134.1, 132.4, 132.3, 129.0, 98.9, 60.7, 56.4. Anal. Calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">17</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">6</ce:inf>S: C, 47.90; H, 4.28; N, 6.99. Found: C, 48.06; H, 4.26; N, 7.02.</ce:para>
                        <ce:para id="p0315" view="all">
                           <ce:italic>4-chloro-N-(3-chloro-4-fluorophenyl)-3-sulfamoylbenzamide (B7).</ce:italic> Yield/%: 14.7%; MP: 244.4–246.2 °C; ESI-MS: 363.12 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.69 (s, 1H), 8.51 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.15 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 8.03 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 6.6 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.83 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.75 (s, 2H), 7.68 (m, 1H), 7.42 (t, 1H, <ce:italic>J</ce:italic> = 9.0 Hz); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.2, 155.0, 153.4, 141.9, 136.6, 134.4, 133.9, 132.4, 129.1, 122.6, 121.5, 119.8, 117.6. Anal. Calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">9</ce:inf>Cl<ce:inf loc="post">2</ce:inf>FN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 43.07; H, 2.51; N, 7.73. Found: C, 43.01; H, 2.51; N, 7.75.</ce:para>
                        <ce:para id="p0320" view="all">
                           <ce:italic>4-chloro-N-(4-chloro-3-fluorophenyl)-3-sulfamoylbenzamide (B8).</ce:italic> Yield/%: 91.1%; MP: 248.3–250.1 °C; ESI-MS: 362.96 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 8.5 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.16 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.92 (m, 1H), 7.84 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.57 (m, 2H), (The chemical shift of CONH and SO2NH2 were not shown); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.5, 158.3, 156.6, 142.2, 140.1, 134.5, 133.9, 132.3, 131.1, 129.1, 118.0, 114.3, 109.2. Anal. Calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">9</ce:inf>Cl<ce:inf loc="post">2</ce:inf>FN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 43.07; H, 2.51; N, 7.73. Found: C, 43.01; H, 2.49; N, 7.69.</ce:para>
                        <ce:para id="p0325" view="all">
                           <ce:italic>4-chloro-3-sulfamoyl-N-(2-(trifluoromethyl)phenyl)benzamide (B9).</ce:italic> Yield/%: 87.5%; MP: 184.4–185.7 °C; ESI-MS: 378.98 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.50 (s, 1H), 8.54 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.15 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.86 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.82 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.75 (m, 3H), 7.54 (m, 2H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.5, 141.9, 140.1, 134.5, 133.9, 132.7, 132.4, 130.1, 129.9, 129.1, 124.6, 123.8, 121.0, 117.2. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">10</ce:inf>ClF<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 44.36; H, 2.67; N, 7.39. Found: C, 44.23; H, 2.66; N, 7.35.</ce:para>
                        <ce:para id="p0330" view="all">
                           <ce:italic>4-chloro-3-sulfamoyl-N-(3-(trifluoromethyl)phenyl)benzamide (B10).</ce:italic> Yield/%: 88.4%; MP: 182.1–184.2 °C; ESI-MS: 378.98 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.82 (s, 1H), 8.56 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.20 (m, 2H), 8.05 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.87 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.77 (m, 2H), 7.63 (t, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.45 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.5, 141.9, 140.1, 134.5, 133.9, 132.7, 132.4, 130.6, 130.1, 129.9, 129.1, 124.6, 121.0, 117.2. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">10</ce:inf>ClF<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 44.36; H, 2.67 N, 7.39. Found: C, 44.13; H, 2.66; N, 7.40.</ce:para>
                        <ce:para id="p0335" view="all">
                           <ce:italic>4-chloro-3-sulfamoyl-N-(4-(trifluoromethyl)phenyl)benzamide (B11).</ce:italic> Yield/%: 44.3%; MP: 179.6–181.7 °C; ESI-MS: 378.98 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.85 (s, 1H), 8.54 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.20 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 8.00 (d, 2H, <ce:italic>J</ce:italic> = 9.0 Hz), 7.86 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.75 (m, 4H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.6, 143.0, 141.9, 134.5, 134.0, 132.8, 132.4, 129.2, 126.6, 125.8, 124.7, 124.5, 124.0, 121.0. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">10</ce:inf>ClF<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 44.36; H, 2.67; N, 7.39. Found: C, 44.07; H, 2.67; N, 7.39.</ce:para>
                        <ce:para id="p0340" view="all">
                           <ce:italic>tert-butyl 4-(4-chloro-3-sulfamoylbenzamido)benzoate (B12).</ce:italic> Yield/%: 77.2%; MP: 298.2–301.8 °C; ESI-MS: 411.22 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.81 (s, 1H), 8.53 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.20 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.91 (d, 4H, <ce:italic>J</ce:italic> = 3.0 Hz), 7.85 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.76 (s, 2H), 1.55 (s, 9H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 165.2, 164.5, 143.5, 141.8, 134.4, 134.1, 132.7, 132.3, 130.6, 129.2, 127.1, 120.3, 81.0, 28.5. Anal. Calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">19</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">5</ce:inf>S: C, 52.57; H, 4.67; N, 6.81. Found: C, 52.13; H, 4.66; N, 6.84.</ce:para>
                        <ce:para id="p0345" view="all">
                           <ce:italic>2-(4-chloro-3-sulfamoylbenzamido)-4,5-dimethoxybenzoic acid (B13).</ce:italic> Yield/%: 55.2%; MP: 284.1–286.1 °C; ESI-MS: 414.99 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 13.68 (br-s, 1H), 12.44 (s, 1H), 8.59 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.43 (s, 1H), 8.12 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.90 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.79 (s, 2H), 7.50 (s, 1H), 3.87 (s, 3H), 3.80 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 170.5, 162.9, 153.8, 144.7, 142.2, 136.9, 134.7, 134.0, 133.0, 131.8, 128.3, 113.5, 109.0, 104.1, 56.2. Anal. Calcd for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">15</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 46.29; H, 3.65; N, 6.75. Found: C, 46.01; H, 3.66; N, 6.73.</ce:para>
                        <ce:para id="p0350" view="all">
                           <ce:italic>4-chloro-N-(4-morpholinophenyl)-3-sulfamoylbenzamide (B14).</ce:italic> Yield/%: 23.6%; MP: 281.8–285.1 °C; ESI-MS: 396.00 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.56 (s, 1H), 8.61 (s, 1H), 8.23 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.78 (m, 3H), 7.69 (d, 2H, <ce:italic>J</ce:italic> = 7.8 Hz), 6.94 (d, 2H, <ce:italic>J</ce:italic> = 9.0 Hz), 3.73 (t, 4H, <ce:italic>J</ce:italic> = 4.2 Hz), 3.07 (t, 4H, <ce:italic>J</ce:italic> = 4.2 Hz); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.8, 153.2, 145.1, 136.2, 135.6, 134.5, 131.2, 129.8, 129.1, 125.6, 102.0, 60.7, 56.4. Anal. Calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">18</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 51.53; H, 4.59; N, 10.61. Found: C, 51.27; H, 4.58; N, 10.57.</ce:para>
                        <ce:para id="p0355" view="all">
                           <ce:italic>4-chloro-N-(perfluorophenyl)-3-sulfamoylbenzamide (B15).</ce:italic> Yield/%: 26.8%; MP: 177.2–178.4 °C; ESI-MS: 400.93 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.92 (s, 1H), 8.59 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.20 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.88 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.78 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.3, 142.0, 135.2, 133.0, 132.8, 131.9, 129.3, 113.3. Anal. Calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">6</ce:inf>ClF<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 38.93; H, 1.51; N, 6.99. Found: C, 38.73; H, 1.50; N, 6.97.</ce:para>
                        <ce:para id="p0360" view="all">
                           <ce:italic>4-chloro-N-(4-(4-methylpiperazin-</ce:italic>1-yl<ce:italic>)phenyl)-3-sulfamoylbenzamide (B16).</ce:italic> Yield/%: 21.6%; MP: 282.3–285.7 °C; ESI-MS: 409.07 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.46 (s, 1H), 8.56 (d, 1H, <ce:italic>J</ce:italic> = 1.2 Hz), 8.16 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.79 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.67 (m, 2H), 7.62 (d, 2H, <ce:italic>J</ce:italic> = 9.0 Hz), 6.93 (d, 2H, <ce:italic>J</ce:italic> = 9.0 Hz), 3.10 (t, 4H, <ce:italic>J</ce:italic> = 4.8 Hz), 2.45 (t, 4H, <ce:italic>J</ce:italic> = 4.8 Hz), 2.22 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.5, 141.7, 134.5, 133.8, 132.5, 132.2, 131.3, 129.0, 122.3, 116.1, 52.5, 52.0, 48.6. Anal. Calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">21</ce:inf>ClN<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 52.82; H, 5.19; N, 13.70. Found: C, 52.67; H, 5.18; N, 13.71.</ce:para>
                        <ce:para id="p0365" view="all">
                           <ce:italic>4-chloro-N-(4-(N-(diaminomethylene)sulfamoyl)phenyl)-3-sulfamoylbenzamide (B17).</ce:italic> Yield/%: 79.1%; MP: 243.8–246.4 °C; ESI-MS: 431.99 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.78 (s, 1H), 8.53 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.19 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.84 (m, 3H), 7.75 (m, 4H), 6.69 (br-s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.5, 158.7, 141.8, 141.8, 140.2, 134.4, 134.1, 132.7, 132.4, 129.2, 127.1, 120.5. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">14</ce:inf>ClN<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: C, 38.94; H, 3.27; N, 16.22. Found: C, 38.90; H, 3.26; N, 16.16.</ce:para>
                        <ce:para id="p0370" view="all">
                           <ce:italic>4-chloro-3-sulfamoyl-N-(3-sulfamoylphenyl)benzamide (B18).</ce:italic> Yield/%: 79.5%; MP: 171.5–173.3 °C; ESI-MS: 389.92 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.83 (s, 1H), 8.56 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.32 (d, 1H, <ce:italic>J</ce:italic> = 1.2 Hz), 8.21 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.97 (m, 1H), 7.86 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.77 (s, 2H), 7.57 (m, 2H), 7.41 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.4, 145.2, 141.8, 139.7, 134.4, 134.0, 132.7, 132.4, 130.1, 129.2, 124.0, 121.8, 118.1. Anal. Calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">12</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S<ce:inf loc="post">2</ce:inf>: C, 40.02; H, 3.11; N, 10.77. Found: C, 39.95; H, 3.10; N, 10.74.</ce:para>
                        <ce:para id="p0375" view="all">
                           <ce:italic>4-chloro-N-(2-chloro-4-nitrophenyl)-3-sulfamoylbenzamide (B19).</ce:italic> Yield/%: 28.6%; MP: 246.6–248.1 °C; ESI-MS: 390.01 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.72 (s, 1H), 8.57 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.43 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.28 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 9.0 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 8.20 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 8.00 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz), 7.88 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.79 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.4, 145.6, 141.9, 141.6, 134.9, 133.0, 132.9, 132.6, 129.4, 129.3, 128.1, 125.6, 123.6. Anal. Calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">9</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">5</ce:inf>S: C, 39.98; H, 2.33; N, 10.76. Found: C, 39.76; H, 2.33; N, 10.76.</ce:para>
                        <ce:para id="p0380" view="all">
                           <ce:italic>4-chloro-N-(2-methoxybenzyl)-3-sulfamoylbenzamide (X1).</ce:italic> Yield/%: 29.7%; MP: 188.2–191.5 °C; ESI-MS: 355.09 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.16 (t, 1H, <ce:italic>J</ce:italic> = 5.4 Hz), 8.50 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.10 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.77 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.71 (s, 2H), 7.23 (m, 1H), 7.17 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.00 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 6.91 (t, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 4.46 (d, 2H, <ce:italic>J</ce:italic> = 6.0 Hz), 3.82 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 165.0, 157.2, 141.7, 133.9, 133.8, 132.3, 132.2, 128.8, 128.7, 128.0, 127.0, 120.7, 111.1, 56.0, 38.5. Anal. Calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">15</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 50.73; H, 4.27; N, 7.89. Found: C, 50.51; H, 4.28; N, 7.88.</ce:para>
                        <ce:para id="p0385" view="all">
                           <ce:italic>4-chloro-N-(3-methoxybenzyl)-3-sulfamoylbenzamide (X2).</ce:italic> Yield/%: 22.8%; MP: 189.1–191.0 °C; ESI-MS: 355.16 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.32 (t, 1H, <ce:italic>J</ce:italic> = 6.0 Hz), 8.49 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.08 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.77 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.71 (s, 2H), 6.81 (m, 4H), 4.46 (d, 2H, <ce:italic>J</ce:italic> = 6.0 Hz), 3.73 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.9, 161.7, 159.9, 141.7, 141.4, 133.9, 132.3, 132.1, 130.0, 128.8, 120.0, 113.7, 112.8, 55.6, 43.4. Anal. Calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">15</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 50.73; H, 4.27; N, 7.89. Found: C, 50.35; H, 4.26; N, 7.89.</ce:para>
                        <ce:para id="p0390" view="all">
                           <ce:italic>4-chloro-N-(4-methoxybenzyl)-3-sulfamoylbenzamide (X3).</ce:italic> Yield/%: 82.2%; MP: 184.9–186.2 °C; ESI-MS: 355.09 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.27 (t, 1H, <ce:italic>J</ce:italic> = 5.4 Hz), 8.48 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.06 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.76 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.70 (s, 2H), 7.25 (d, 2H, <ce:italic>J</ce:italic> = 8.4 Hz), 6.89 (d, 2H, <ce:italic>J</ce:italic> = 8.4 Hz), 4.41 (d, 2H, <ce:italic>J</ce:italic> = 5.4 Hz), 3.72 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.7, 161.5, 158.9, 141.7, 134.0, 133.8, 132.3, 132.1, 131.8, 131.5, 129.3, 128.8, 114.3. Anal. Calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">15</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">4</ce:inf>S: C, 50.73; H, 4.27; N, 7.89. Found: C, 50.43; H, 4.26; N, 7.91.</ce:para>
                        <ce:para id="p0395" view="all">
                           <ce:italic>4-chloro-N-(2,3-dichlorobenzyl)-3-sulfamoylbenzamide (X4).</ce:italic> Yield/%: 85.3%; MP: 174.2–177.6 °C; ESI-MS: 392.92 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.41 (t, 1H, <ce:italic>J</ce:italic> = 6.0 Hz), 8.51 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.11 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.79 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.57 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 6.6 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.55 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.34 (m, 3H), 4.58 (d, 2H, <ce:italic>J</ce:italic> = 5.4 Hz); <ce:sup loc="post">13</ce:sup>C NMR (151 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 165.1, 141.8, 139.3, 134.1, 133.5, 132.3, 132.3, 130.6, 129.7, 128.8, 128.7, 128.0, 42.2. Anal. Calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>Cl<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S: C, 42.68; H, 2.82; N, 7.11. Found: C, 42.54; H, 2.81; N, 7.14.</ce:para>
                        <ce:para id="p0400" view="all">
                           <ce:italic>4-chloro-N-(2-methoxybenzyl)-3-sulfamoylbenzamide (X5).</ce:italic> Yield/%: 87.9%; MP: 199.2–202.0 °C; ESI-MS: 414.96 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 9.28 (t, 1H, <ce:italic>J</ce:italic> = 5.5 Hz), 8.50 (d, 1H, <ce:italic>J</ce:italic> = 1.5 Hz), 8.09 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.5 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.0 Hz), 7.77 (d, 1H, <ce:italic>J</ce:italic> = 8.0 Hz), 7.68 (s, 2H), 6.66 (s, 2H), 4.44 (d, 1H, <ce:italic>J</ce:italic> = 5.5 Hz), 3.76 (s, 6H), 3.64 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.3, 152.8, 141.2, 136.6, 134.8, 133.4, 133.2, 131.6, 131.5, 128., 105.0, 60.0, 55.9, 43.1. Anal. Calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">19</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">6</ce:inf>S: C, 49.17; H, 4.63; N, 6.75. Found: C, 49.03; H, 4.61; N, 6.77.</ce:para>
                        <ce:para id="p0405" view="all">
                           <ce:italic>3-(N-acryloylsulfamoyl)-4-chloro-N-(3, 4, 5-trimethoxyphenyl)benzamide (Y1).</ce:italic> Yield/%: 55.9%; MP: 174.9–177.0 °C; ESI-MS: 455.20 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.56 (s, 1H), 8.58 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.22 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz), 7.71 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz), 7.25 (s, 2H), 6.05 (m, 2H), 5.62 (s, 1H), 3.77 (s, 6H), 3.64 (s, 3H), (The chemical shift of SO2NHCO was not shown); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.6, 162.9, 152.6, 137.0, 134.6, 134.2, 133.9, 133.6, 133.4, 131.9, 131.4, 98.6, 60.1, 55.8. Anal. Calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">19</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 50.12; H, 4.22; N, 6.16. Found: C, 49.97; H, 4.22; N, 6.14.</ce:para>
                        <ce:para id="p0410" view="all">
                           <ce:italic>4-chloro-3-(N-methacryloylsulfamoyl)-N-(3,4,5-trimethoxyphenyl)benzamide (Y2).</ce:italic> Yield/%: 44.3%; MP: 184.8–187.8 °C; ESI-MS: 469.23 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 12.69 (br-s, 1H), 10.58 (s, 1H), 8.59 (s, 1H), 8.23 (m, 1H), 7.74 (m, 1H), 7.25 (s, 2H), 5.83 (m, 1H), 5.49 (m, 1H), 3.77 (s, 6H), 3.64 (s, 3H), 1.75 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.6, 162.9, 153.2, 152.6, 137.0, 134.6, 134.0, 133.6, 133.5, 131.9, 131.4, 115.6, 106.8, 98.6, 60.1, 56.2, 20.0. Anal. Calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">21</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 51.18; H, 4.52; N, 5.97. Found: C, 51, 04; H, 4.52; N, 5.94.</ce:para>
                        <ce:para id="p0415" view="all">
                           <ce:italic>4-chloro-3-(N-(3-methylbut-2-enoyl)sulfamoyl)-N-(3,4,5-trimethoxyphenyl)benzamide (Y3).</ce:italic> Yield/%: 41.6%; MP: 194.9–196.2 °C; ESI-MS: 483.19 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 12.4 (br-s, 1H), 10.51 (s, 1H), 8.64 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.25 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.87 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.19 (s, 2H), 5.80 (s, 1H), 3.78 (s, 6H), 3.65 (s, 3H), 1.97 (s, 3H), 1.84 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.6, 162.9, 153.2, 152.6, 137.0, 134.6, 134.2, 133.9, 133.6, 133.4, 131.9, 131.5, 131.4, 98.6, 60.1, 55.8, 27.3, 20.0. Anal. Calcd for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">23</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 52.18; H, 4.81; N, 5.80. Found: C, 52.02; H, 4.80; N, 5.82.</ce:para>
                        <ce:para id="p0420" view="all">
                           <ce:italic>3-(N-acetylsulfamoyl)-4-chloro-N-(3, 4, 5-trimethoxyphenyl)benzamide (Y4).</ce:italic> Yield/%: 49.1%; MP: 210.0–211.5 °C; ESI-MS: 443.21 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 12.66 (br-s, 1H), 10.50 (s, 1H), 8.61 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.23 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.88 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.19 (s, 2H), 3.78 (s, 6H), 3.65 (s, 3H), 1.98 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 169.1, 162.9, 152.6, 134.6, 134.2, 133.9, 133.7, 133.5, 131.9, 131.3, 98.6, 60.1, 55.8.23.1. Anal. Calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">19</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 48.77; H, 4.33; N, 6.32. Found: C, 48.67; H, 4.32; N, 6.33.</ce:para>
                        <ce:para id="p0425" view="all">
                           <ce:italic>4-chloro-3-(N-propionylsulfamoyl)-N-(3,4,5-trimethoxyphenyl)benzamide (Y5).</ce:italic> Yield/%: 33.9%; MP: 217.9–219.2 °C; ESI-MS: 457.24 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 12.61 (br-s, 1H), 10.50 (s, 1H), 8.62 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.24 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.86 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.19 (s, 2H), 3.78 (s, 6H), 3.65 (s, 3H), 2.27 (q, 2H, <ce:italic>J</ce:italic> = 7.8 Hz), 0.90 (t, 3H, <ce:italic>J</ce:italic> = 7.8 Hz); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 172.8, 162.9, 152.6, 134.7, 134.2, 133.8, 133.6, 133.3, 131.8, 131.3, 98.6, 60.1, 55.8, 28.9, 8.4. Anal. Calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">21</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 49.90; H, 4.64; N, 6.13. Found: C, 49.87; H, 4.64; N, 6.16.</ce:para>
                        <ce:para id="p0430" view="all">
                           <ce:italic>(E)-3-(N-(but-2-enoyl)sulfamoyl)-4-chloro-N-(3,4,5-trimethoxyphenyl)benzamide (Y6).</ce:italic> Yield/%: 39.9%; MP: 198.0–199.7 °C; ESI-MS: 469.16 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 12.66 (br-s, 1H), 10.50 (s, 1H), 8.64 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.25 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.86 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.19 (s, 2H), 6.77 (m, 1H), 6.01 (d, 1H, <ce:italic>J</ce:italic> = 15.6 Hz), 3.78 (s, 6H), 3.65 (s, 3H), 1.82 (d, 3H, <ce:italic>J</ce:italic> = 5.4 Hz); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 162.9, 152.6, 134.6, 134.208, 133.9, 133.6, 131.9, 131.4, 98.6, 60.1, 55.8, 17.7. Anal. Calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">21</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 51.18; H, 4.52; N, 5.97. Found: C, 51.09; H, 4.51; N, 5.97.</ce:para>
                        <ce:para id="p0435" view="all">
                           <ce:italic>3-(N-benzoylsulfamoyl)-4-chloro-N-(3, 4, 5-trimethoxyphenyl)benzamide (Z1).</ce:italic> Yield/%: 22.9%; MP: 201.0–203.5 °C; ESI-MS: 505.13 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.42 (s, 1H), 8.59 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.01 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.89 (m, 2H), 7.57 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.39 (m, 2H), 7.33 (t, 1H, <ce:italic>J</ce:italic> = 14.4 Hz), 7.24 (s, 2H), 3.78 (s, 6H), 3.65 (s, 3H), (The chemical shift of SO2NHCO was not shown); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.2, 163.0, 152.6, 134.7, 134.2, 133.9, 133.5, 131.8, 131.4, 130.7, 129.3, 113.9, 113.3, 98.6, 60.1, 55.8. Anal. Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">21</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 54.66; H, 4.20; N, 5.55. Found: C, 54.57; H, 4.21; N, 5.57.</ce:para>
                        <ce:para id="p0440" view="all">
                           <ce:italic>4-chloro-3-(N-(2-methoxybenzoyl)sulfamoyl)-N-(3,4,5-trimethoxyphenyl)benzamide (Z2).</ce:italic> Yield/%: 29.8%; MP: 211.6–213.2 °C; ESI-MS: 535.14 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 12.48 (br-s, 1H), 10.52 (s, 1H), 8.70 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.29 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.91 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.20 (s, 2H), 6.99 (m, 4H), 3.84 (s, 3H), 3.789 (s, 6H), 3.66 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 162.9, 157.0, 152.6, 134.7, 134.2, 133.9, 133.6, 133.4, 132.9, 132.4, 132.0, 131.5, 130.7, 130.5, 129.4, 120.4, 120.0, 112.4, 112.2, 112.0, 98.6, 60.1, 55.9, 55.8. Anal. Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">23</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">8</ce:inf>S: C, 53.84; H, 4.34; N, 5.23. Found: C, 53.81; H, 4.35; N, 5.22.</ce:para>
                        <ce:para id="p0445" view="all">
                           <ce:italic>4-chloro-3-(N-(3-methoxybenzoyl)sulfamoyl)-N-(3,4,5-trimethoxyphenyl)benzamide (Z3).</ce:italic> Yield/%: 33.9%; MP: 214.8–215.1 °C; ESI-MS: 535.16 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.46 (s, 1H), 8.60 (s, 1H), 8.42 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.85 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.32 (m, 3H), 7.19 (s, 2H), 7.08 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 3.77 (s, 3H), 3.68 (s, 6H), 3.62 (s, 3H), (The chemical shift of SO2NHCO was not shown); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 172.4, 159.0, 158.8, 153.1, 135.9, 135.0, 129.7, 121.2, 120.8, 118.2, 114.0, 113.1, 106.4, 98.5, 60.0, 56.2, 55.8. Anal. Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">23</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">8</ce:inf>S: C, 53.84; H, 4.34; N, 5.23. Found: C, 53.82; H, 4.33; N, 5.23.</ce:para>
                        <ce:para id="p0450" view="all">
                           <ce:italic>4-chloro-3-(N-(4-methoxybenzoyl)sulfamoyl)-N-(3,4,5-trimethoxyphenyl)benzamide (Z4).</ce:italic> Yield/%: 36.8%; MP: 207.7–209.4 °C; ESI-MS: 535.23 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 12.91 (br-s, 1H), 10.52 (s, 1H), 8.70 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.25 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.92 (d, 2H, <ce:italic>J</ce:italic> = 9.0 Hz), 7.83 (m, 1H), 7.20 (s, 2H), 7.02 (d, 2H, <ce:italic>J</ce:italic> = 9.0 Hz), 3.82 (s, 3H), 3.79 (s, 6H), 3.65 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 163.2, 163.0, 152.6, 134.7, 134.2, 133.9, 133.6, 131.8, 131.4, 130.7, 129.3, 113.9, 113.3, 98.6, 60.1, 55.8, 55.5, 55.3. Anal. Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">23</ce:inf>ClN<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">8</ce:inf>S: C, 53.84; H, 4.34; N, 5.23. Found: C, 52.79; H, 4.33; N, 5.21.</ce:para>
                        <ce:para id="p0455" view="all">
                           <ce:italic>4-chloro-3-(N-(3-nitrobenzoyl)sulfamoyl)-N-(3,4,5-trimethoxyphenyl)benzamide (Z5).</ce:italic> Yield/%: 37.5%; MP: 217.8–218.2 °C; ESI-MS: 550.15 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.42 (s, 1H), 8.68 (t, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.59 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.23 (m, 3H), 8.01 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 8.4 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 2.4 Hz), 7.57 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.24 (s, 2H), 3.78 (s, 6H), 3.65 (s, 3H), (The chemical shift of SO2NHCO was not shown); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 164.1, 159.0, 158.8, 152.6, 147.5, 135.0, 134.5, 130.6, 130.2, 129.3, 122.7, 118.2, 114.0, 113.2, 106.4, 98.5, 60.1, 55.8. Anal. Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">9</ce:inf>S: C, 50.19; H, 3.67; N, 7.64. Found: C, 50.15; H, 3.67; N, 7.65.</ce:para>
                        <ce:para id="p0460" view="all">
                           <ce:italic>4-chloro-3-(N-(3,5-dimethoxybenzoyl)sulfamoyl)-N-(3,4,5-trimethoxyphenyl)benzamide (Z6).</ce:italic> Yield/%: 21.3%; MP: 199.0–202.2 °C; ESI-MS: 565.12 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.43 (s, 1H), 8.57 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.01 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.55 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.25 (s, 2H), 7.07 (s, 2H), 6.50 (s, 1H), 3.77 (s, 6H), 3.72 (s, 6H), 3.64 (s, 3H), (The chemical shift of SO2NHCO was not shown); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 167.1, 163.9, 159.0, 153.1, 147.5, 134.9, 131.6, 129.7, 121.2, 120.8, 118.2, 113.9, 113.1, 106.3, 102.0, 98.5, 60.0, 56.2, 55.8, 55.3, 55.3, 55.0. Anal. Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">9</ce:inf>S: C, 48.85; H, 3.58; N, 7.43. Found: C, 48.81; H, 3.57; N, 7.45.</ce:para>
                        <ce:para id="p0465" view="all">
                           <ce:italic>N-((2-chloro-5-((3,4,5-trimethoxyphenyl)carbamoyl)phenyl)sulfonyl)-2,6-dimethoxybenzamide (Z7).</ce:italic> Yield/%: 19.6%; MP: 194.8–196.4 °C; ESI-MS: 565.12 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.43 (s, 1H), 8.57 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.01 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.55 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.25 (s, 2H), 7.07 (d, 2H, <ce:italic>J</ce:italic> = 2.4 Hz), 6.50 (t, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 3.77 (s, 6H), 3.72 (s, 6H), 3.64 (s, 3H), (The chemical shift of SO2NHCO was not shown); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 169.4, 164.1, 159.7, 152.6, 144.1, 141.4, 135.0, 133.9, 133.6, 132.8, 130.2, 129.7, 106.1, 102.4, 98.5, 60.1, 55.8, 55.1. Anal. Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">9</ce:inf>S: C, 48.85; H, 3.58; N, 7.43. Found: C, 48.88; H, 3.57; N, 7.42.</ce:para>
                        <ce:para id="p0470" view="all">
                           <ce:italic>6-chloro-N-((2-chloro-5-((3,4,5-trimethoxyphenyl)carbamoyl)phenyl)sulfonyl)nicotinamide (Z8).</ce:italic> Yield/%: 24.5%; MP: 191.2–192.8 °C; ESI-MS: 540.07 [M+H]<ce:sup loc="post">+</ce:sup>; <ce:sup loc="post">1</ce:sup>H NMR (600 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 10.38 (s, 1H), 8.80 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.58 (d, 1H, <ce:italic>J</ce:italic> = 1.8 Hz), 8.19 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.97 (dd, 1H, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>1</ce:italic>
                           </ce:inf> = 7.8 Hz, <ce:italic>J</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>2</ce:italic>
                           </ce:inf> = 1.8 Hz), 7.57 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.48 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.22 (s, 2H), 3.78 (s, 6H), 3.65 (s, 3H), (The chemical shift of SO2NHCO was not shown); <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>): 166.9, 164.1, 152.6, 151.4, 150.0, 139.3, 135.0, 133.6, 133.5, 133.0, 130.6, 130.1, 130.0, 123.4, 98.5, 60.1, 55.8. Anal. Calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">19</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">7</ce:inf>S: C, 48.90; H, 3.54; N, 7.78. Found: C, 48.82; H, 3.54; N, 7.77.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0120">Oil-water partition coefficient (logP) measurement experiment</ce:section-title>
                     <ce:para id="p0475" view="all">At room temperature, take two larger Erlenmeyer flasks, add n-octanol and enough water, water and enough n-octanol, respectively, then place them in a constant temperature shaker at 150•r/min and shake for 24 h, then transfer into the normal pressure separating funnel, and then obtain water-saturated n-octanol and n-octanol-saturated water, for use. Weigh 2 mg of the target compound accurately, place it in a 2 ml brown volumetric flask, add anhydrous methanol to ultrasonically dissolve, dilute to the mark and shake well to obtain a 1 mg/ml reference substance stock solution. Dilute and prepare 1 μg/ml, 1.5 μg/ml, 2 μg/ml, 2.5 μg/ml, 5 μg/ml, 10 μg/ml series of reference standard solutions, and draw the standard curve by UV–visible spectrophotometer. Excessively dissolve the analyte in water-saturated n-octanol, shake at 150•r/min for 24 h in a constant temperature shaker to make a saturated solution. After standing still, centrifuge, and take 1 ml of the supernatant in a 4 ml centrifuge tube. Add 1 ml of n-octanol saturated water, place it in a constant temperature shaker at 150•r/min and shake for 24 h, let it stand for 8 h and then centrifuge, pipette an appropriate amount of n-octanol phase before and after equilibration, dilute with methanol appropriately, and then pass the previously drawn standard. The curve obtains the n-octanol phase concentration before and after equilibrium, C<ce:inf loc="post">0</ce:inf> and C<ce:inf loc="post">1</ce:inf>, and the n-octanol saturated aqueous phase concentration is C<ce:inf loc="post">w</ce:inf> = C<ce:inf loc="post">0</ce:inf>–C<ce:inf loc="post">1</ce:inf>, that is, logP<ce:inf loc="post">ow</ce:inf> = log<ce:inf loc="post">10</ce:inf> C<ce:inf loc="post">0</ce:inf>/C<ce:inf loc="post">w</ce:inf>.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0125">Cell lines and reagents</ce:section-title>
                     <ce:para id="p0480" view="all">Human colon cell lines (HCT-116 and SW480), human breast cancer cell line (MDA-MB-231) and human pancreatic cancer cell line (L3.6) were purchased from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). Human colon cancer cells HCT-116 and SW480 were cultured in RPMI 1640 medium supplemented with 10% (vol/vol) FBS, 50 μg/ml penicillin and 50 μg/ml streptomycin; Human pancreatic cancer cell line L3.6 was cultured in Dulbecco modified Eagle medium (DMEM) medium supplemented with 10% (vol/vol) FBS, 50 μg/ml penicillin and 50 μg/ml streptomycin; Human breast cancer cell MDA-MB-231 was cultured in L15 medium supplemented with 10% (vol/vol) FBS, 50 μg/ml penicillin and 50 μg/ml streptomycin; All cells were cultured at 37 °C under a 5% CO<ce:inf loc="post">2</ce:inf> and 90% humidified atmosphere.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0130">Cell viability assays</ce:section-title>
                     <ce:para id="p0485" view="all">In this experiment, MTT assay was used to detect cell viability in breast cancer cells MDA-MB-231, colon cancer cells HCT-116, SW480 and pancreatic cancer cells L3.6. Each tumor cell (MDA-MB-231, HCT-116, SW480 and L3.6) in the logarithmic growth phase was cultured in a 96-well plate at a concentration of 6 × 10<ce:sup loc="post">3</ce:sup> cells per well, incubated for 24 h at 37 °C. Then, 1 μL of the positive compound Niclosamide and 57 target compound solutions dissolved in DMSO at a final concentration of 10 μM or different concentration gradients (0.1–2 μM) were administered; After 48 h of administration, 20 μL of MTT solution dissolved in PBS to 5 mg/mL was added to each well, and continued to culture for 4 h. Discard the solution in each well, add 150 μL of DMSO to each well to dissolve the formazan crystals and shake it on a shaker for 10 min. Finally, the absorbance of each well at the ultraviolet absorption wavelength of 490 nm was detected by a microplate reader, and the corresponding cell survival rate, inhibition rate or IC<ce:inf loc="post">50</ce:inf> value were calculated. This experiment requires at least three repeated experiments to reduce the experimental error.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.5" view="all">
                     <ce:label>4.5</ce:label>
                     <ce:section-title id="sectitle0135">STAT3 kit</ce:section-title>
                     <ce:para id="p0490" view="all">The PathScan® Phospho-STAT3 (Tyr 705) Sandwich ELISA kit (Cell Signaling Technology, #7300) was used under the guidance of manufacturer’s instructions to measure the level of STAT3 phosphorylation with the treatment of tested compounds. The measurements were repeated at least three times.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.6" view="all">
                     <ce:label>4.6</ce:label>
                     <ce:section-title id="sectitle0140">Western blot analysis</ce:section-title>
                     <ce:para id="p0495" view="all">Breast cancer cells MDA-MB-231 were plated in 6-well plates and cultured overnight; then different concentrations (0 μM, 1 μM, 5 μM, 10 μM) of the active compound B12 and 10 μM Niclosamide were administered for 2 h. The corresponding cells were collected, washed with PBS, and lysed with RIPA buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS) to extract the total proteins. The extracted protein was loaded, subjected to SDS-PAGE electrophoresis, and then the protein was transferred to a PDVF membrane and incubated in the corresponding Primary antibody overnight (STAT3, p-STAT3, p-STAT1, STAT1, Cleaved Caspase-3, Cleaved Caspase-9, Cleaved PARP, Bcl-xl and GAPDH); the next day, the Primary antibody was recovered and labeled and the corresponding Secondary antibody was incubated. Finally, bound immune-complexes were detected using ChemiDOC™ XRS t system (Bio-Rad Laboratories, Hercules, CA).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.7" view="all">
                     <ce:label>4.7</ce:label>
                     <ce:section-title id="sectitle0145">IL-6 induction of STAT3 phosphorylation</ce:section-title>
                     <ce:para id="p0500" view="all">MDA-MB-231 cells were seeded in 6-well plates and allowed to adhere overnight. The following day, the cells were serum-starved. The cells were then left untreated or were treated with B12 (0.5–10 mM) or Niclosamide (10 mM). After 2 h, the untreated and treated cells were stimulated by IL-6 (50 ng/mL). The cells were harvested after 45 min and analyzed by Western blot assay.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.8" view="all">
                     <ce:label>4.8</ce:label>
                     <ce:section-title id="sectitle0150">Kinase inhibition assay</ce:section-title>
                     <ce:para id="p0505" view="all">The procedure was as follows: Prepare 2.5 × enzyme solution; add kinase in 1 kinase base buffer. Prepare 2.5 × peptide solution, add FAM-labeled (GL Biochem) peptide and ATP (Sigma) in a 1 × kinase base buffer. The assay plate already contains 5 μL of compound in 10% DMSO (Sigma). Transfer 2.5 × enzyme solution to the assay plate, add 10 μL of 2.5 × enzyme solution to each well of the 384-well (Corning) assay plate. Incubate at room temperature for 10 min. Transfer 2.5 × peptide solution to the assay plate. Add 10 μL of 2.5 × peptide solution to each well of the 384-well assay plate. Incubate at 28 °C for specified period of time. Add 25 μL of buffer to quench reaction. The data was collected using Caliper. Convert conversion values to inhibition values, percent inhibition = (max-conversion)/(max-min) × 100, that “max” stands for DMSO control; “min” stands for low control. The same method was used to perform the kinase selectivity test of 34 kinases. FLT1and FLT3 were purchased from Invitrogen. AKT1 and AKT2 wrer purchased from BPS. The other 30 kinases were purchased from Carna.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.9" view="all">
                     <ce:label>4.9</ce:label>
                     <ce:section-title id="sectitle0155">Transient transfection and dual luciferase reporter assays</ce:section-title>
                     <ce:para id="p0510" view="all">In 24-well plates MDA-MB-231 cells were seeded at a density of 1.5 × 10<ce:sup loc="post">4</ce:sup> cells per well in DMEM supplemented with 50 mg/ml penicillin, 50 mg/ml streptomycin and 10% (v/v) FBS. Utilizing the method reported, transient transfections were conducted 4 h after plating [30–32]. The amount of transfected DNA including internal control vector renilla and pSTAT3-Luc was 0.5 μg per well. After 6 h of transfection, the cells were treated with 0.1, 0.5, 1.0 μM B12, or 1.0 μM Niclosamide for 24 h, and then reporter activity was determined using dual luciferase reporter assay kit (Thermo Scientific™ Varioskan™ LUX Microplate Luminometer). Each experiment was independently conducted three times, and the results were averaged. The relative luciferase units were expressed as the ratio of absolute activity of firefly luciferase to absolute activity of renilla luciferase.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.10" view="all">
                     <ce:label>4.10</ce:label>
                     <ce:section-title id="sectitle0160">Flow cytometry analysis of apoptotic cells</ce:section-title>
                     <ce:para id="p0515" view="all">MDA-MB-231 cells at a density of 5 × 10<ce:sup loc="post">5</ce:sup> per well were cultured in regular growth medium in 6-well plates for 24 h and treated with different concentrations of B12 or Niclosamide for 24 h. The cells were harvested, washed and stained with 3 μL Annexin V-FITC and 3 μL propidium iodide at room temperature for 15 min and 1 × binding buffer was used for dilution to 500 μL. The cells were then stained with PI, Annexin-V alone as positive control. The samples were measured with a BD Accuri™ C6 flow cytometer (Becton Dickinson) and the data were processed using FlowJo 7.6.1.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.11" view="all">
                     <ce:label>4.11</ce:label>
                     <ce:section-title id="sectitle0165">Colony survival assay</ce:section-title>
                     <ce:para id="p0520" view="all">MDA-MB-231 cells were cultured 1000 per well in 6-well plate with regular growth medium. Cells were treated by B12 (0.1–1 μM) or Niclosamid (1 μM) on the following day for 24 h. Cells were allowed to grow for 10–14 d until the colonies were visible. Crystal violet solution (Sigma, St. Louis, MO, USA) was used to stain the colonies for 4 h and imaged.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.12" view="all">
                     <ce:label>4.12</ce:label>
                     <ce:section-title id="sectitle0170">Transwell assay</ce:section-title>
                     <ce:para id="p0525" view="all">2 × 10<ce:sup loc="post">5</ce:sup> MDA-MB-231 cells were seeded into the upper chamber of one well of a transwell system. Cells were treated by B12 (0.1–1 μM) or Niclosamide (1 μM) and were allowed to migrate through the porous membrane for 24 h at 37 °C in 5% CO<ce:inf loc="post">2</ce:inf>. Then cells in the upper surface of the chamber were completely removed and the lower surfaces of the membranes were stained with crystal violet solution for 20–30 min and imaged.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.13" view="all">
                     <ce:label>4.13</ce:label>
                     <ce:section-title id="sectitle0175">In vivo studies</ce:section-title>
                     <ce:para id="p0530" view="all">In vivo studies, the animal experiments were approved by the Animal Policy and Ethics Committee of Wenzhou Medical University (ID Number: wxdw2018-1206). Six-week old BALB/c (NU/NU) female mice were injected subcutaneously with 0.2 ml of MDA-MB-231 tumor cells, and the number of cells was about 5 × 10<ce:sup loc="post">6</ce:sup> cells. After the tumor developed, the mice were randomly divided into groups. The mice in the blank control group (solvent group), the compound B12 (30 mg/kg) group and the positive control group Niclosamide (30 mg/kg) were intraperitoneally injected or intragastric administered every two days until the mice were sacrificed. The body weight of nude mice was recorded every two days, and the tumor weight was recorded on the day of death of nude mice.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0180">Declaration of competing interest</ce:section-title>
               <ce:para id="p0535" view="all">The authors declare no conflict of interest.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0185">Acknowledgments</ce:section-title>
               <ce:para id="p0540" view="all">This work was commercially supported by the <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (grant no. <ce:grant-number refid="gs1">81373262</ce:grant-number>), the <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100004731" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Natural Science Foundation of Zhejiang Province</ce:grant-sponsor> (grant no. <ce:grant-number refid="gs2">LY16B020010</ce:grant-number>, <ce:grant-number refid="gs2">LY17B020008</ce:grant-number>, <ce:grant-number refid="gs2">LY20H300003</ce:grant-number>, <ce:grant-number refid="gs2">LY21B020011</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0190">Supplementary data</ce:section-title>
                  <ce:para id="p0545" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523421002117/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0195">Supplementary data</ce:section-title>
                  <ce:para id="p0550" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0010" xlink:href="https://doi.org/10.1016/j.ejmech.2021.113362" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2021.113362</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0200">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>172</sb:first-page>
                              <sb:last-page>186</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/cr.2017.146</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">L. Huang, D. Liu, N. Wang, et al., Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia, Cell Res. 28 (2018) 172-186. https://doi.org/10.1038/cr.2017.146.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Miklossy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Hilliard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic modulators of STAT signalling for human diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>611</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrd4088</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">G. Miklossy, T.S. Hilliard, J. Turkson, Therapeutic modulators of STAT signalling for human diseases, Nat. Rev. Drug Discov. 12 (2013) 611-629. https://doi.org/10.1038/nrd4088.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Drewry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>825</sb:first-page>
                              <sb:last-page>833</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1139/o09-044</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">S. Fletcher, J.A. Drewry, V.M. Shahani, et al., Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein, Biochem. Cell Biol. 87 (2009) 825-833. https://doi.org/10.1139/o09-044.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-X.</ce:given-name>
                                 <ce:surname>Lv</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The effect of JAK2 knockout on inhibition of liver tumor growth by inducing apoptosis, autophagy and anti-proliferation via STATs and PI3K/AKT signaling pathways</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomed. Pharmacother.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>84</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1202</sb:first-page>
                              <sb:last-page>1212</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.biopha.2016.09.040</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">Y. Xu, S.-X. Lv, The effect of JAK2 knockout on inhibition of liver tumor growth by inducing apoptosis, autophagy and anti-proliferation via STATs and PI3K/AKT signaling pathways, Biomed. Pharmacother. 84 (2016) 1202-1212. https://doi.org/10.1016/j.biopha.2016.09.040.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ioroi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kanaya</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>24</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1007/s12032-016-0733-0</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">K. Yamamoto, T. Ioroi, K. Kanaya, et al., STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population, Med. Oncol. 33 (2016) 24. https://doi.org/10.1007/s12032-016-0733-0.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PloS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:article-number>e0175466</sb:article-number>
                           <ce:doi>10.1371/journal.pone.0175466</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">M. He, Z. Yang, L. Zhang, et al., Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells, PLoS One. 12 (2017) e0175466. https://doi.org/10.1371/journal.pone.0175466.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.C.W.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Jeyaraj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Sagineedu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SRS06, a new semisynthetic andrographolide derivative with improved anticancer potency and selectivity, inhibits nuclear factor-κB nuclear binding in the A549 non-small cell lung cancer cell line</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>95</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>70</sb:first-page>
                              <sb:last-page>77</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1159/000370313</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">J.C.W. Lim, E.J. Jeyaraj, S.R. Sagineedu, et al., SRS06, a new semisynthetic andrographolide derivative with improved anticancer potency and selectivity, inhibits nuclear factor-κB nuclear binding in the A549 non-small cell lung cancer cell line, Pharmacology. 95 (2015) 70-77. https://doi.org/10.1159/000370313.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-R.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activated STAT3 may participate in tumor progression through increasing CD133/survivin expression in early stage of colon cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Biophys. Res. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>497</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>354</sb:first-page>
                              <sb:last-page>361</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bbrc.2018.02.084</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">W. Li, M.-R. Lee, T. Kim, et al., Activated STAT3 may participate in tumor progression through increasing CD133/survivin expression in early stage of colon cancer, Biochem. Biophys. Res. Commun. 497 (2018) 354-361. https://doi.org/10.1016/j.bbrc.2018.02.084.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.-C.</ce:given-name>
                                 <ce:surname>Hsia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Stopford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 (Stat3) regulates host defense and protects mice against herpes simplex virus-1 (HSV-1) infection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Leukoc. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1053</sb:first-page>
                              <sb:last-page>1064</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1189/jlb.4A1016-199RR</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">H.-C. Hsia, C.M. Stopford, Z. Zhang, et al., Signal transducer and activator of transcription 3 (Stat3) regulates host defense and protects mice against herpes simplex virus-1 (HSV-1) infection, J. Leukoc. Biol. 101 (2017) 1053-1064. https://doi.org/10.1189/jlb.4A1016-199RR.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.-H.</ce:given-name>
                                 <ce:surname>Hung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.-Y.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-S.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alternative roles of STAT3 and MAPK signaling pathways in the MMPs activation and progression of lung injury induced by cigarette smoke exposure in ACE2 knockout mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Biol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>454</sb:first-page>
                              <sb:last-page>465</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.7150/ijbs.13379</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">Y.-H. Hung, W.-Y. Hsieh, J.-S. Hsieh, et al., Alternative Roles of STAT3 and MAPK Signaling Pathways in the MMPs Activation and Progression of Lung Injury Induced by Cigarette Smoke Exposure in ACE2 Knockout Mice, Int. J. Biol. Sci. 12 (2016) 454-465. https://doi.org/10.7150/ijbs.13379.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dihydroartemisinin as a putative STAT3 inhibitor, suppresses the growth of head and neck squamous cell carcinoma by targeting jak2/STAT3 signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PloS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:article-number>e0147157</sb:article-number>
                           <ce:doi>10.1371/journal.pone.0147157</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">L. Jia, Q. Song, C. Zhou, et al., Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling, PLoS One. 11 (2016) e0147157. https://doi.org/10.1371/journal.pone.0147157.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Chemother. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>917</sb:first-page>
                              <sb:last-page>922</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s00280-015-2710-2</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">Y. Yu, Q. Zhao, Z. Wang, et al., Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies, Cancer Chemother. Pharmacol. 75 (2015) 917-922. https://doi.org/10.1007/s00280-015-2710-2.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and biological evaluation of benzyloxyphenyl-methylaminophenol derivatives as STAT3 signaling pathway inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <ce:doi>10.1016/j.bmc.2016.04.022</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">D. Gao, Q. Xiao, M. Zhang, et al., Design, synthesis and biological evaluation of benzyloxyphenyl-methylaminophenol derivatives as STAT3 signaling pathway inhibitors, Bioorg. Med. Chem. (2016). https://doi.org/10.1016/j.bmc.2016.04.022.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of C3-substituted β-carboline-based histone deacetylase inhibitors with potent antitumor activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>646</sb:first-page>
                              <sb:last-page>651</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/cmdc.201700133</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">Y. Ling, J. Feng, L. Luo, et al., Design and Synthesis of C3-Substituted β-Carboline-Based Histone Deacetylase Inhibitors with Potent Antitumor Activities, ChemMedChem. 12 (2017) 646-651. https://doi.org/10.1002/cmdc.201700133.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Jang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-Y.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.-R.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evaluation of antitumor activity of Artemisia capillaris extract against hepatocellular carcinoma through the inhibition of IL-6/STAT3 signaling axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>526</sb:first-page>
                              <sb:last-page>532</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.3892/or.2016.5283</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">E. Jang, S.-Y. Kim, N.-R. Lee, et al., Evaluation of antitumor activity of Artemisia capillaris extract against hepatocellular carcinoma through the inhibition of IL-6/STAT3 signaling axis, Oncol. Rep. 37 (2017) 526-532. https://doi.org/10.3892/or.2016.5283.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>You</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of STAT3 in autophagy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Autophagy</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>729</sb:first-page>
                              <sb:last-page>739</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/15548627.2015.1017192</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">L. You, Z. Wang, H. Li, et al., The role of STAT3 in autophagy, Autophagy. 11 (2015) 729-739. https://doi.org/10.1080/15548627.2015.1017192.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>X</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.Y.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Broad spectrum antiviral agent Niclosamide and its therapeutic potential</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Infect. Dis.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>909</sb:first-page>
                              <sb:last-page>915</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acsinfecdis.0c00052</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">X J, Shi P Y, Li H, et al., Broad spectrum antiviral agent Niclosamide and its therapeutic potential, ACS Infect. Dis., (2020)909-915. https://dx.doi.org/10.1021/acsinfecdis.0c00052</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>454</sb:first-page>
                              <sb:last-page>459</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ml100146z</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">X. Ren, L. Duan, Q. He, et al., Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway, ACS Med. Chem. Lett. 1 (2010) 454-459. https://doi.org/10.1021/ml100146z.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Cerles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Benoit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chéreau</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Niclosamide inhibits oxaliplatin neurotoxicity while improving colorectal cancer therapeutic response</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>300</sb:first-page>
                              <sb:last-page>311</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1535-7163.MCT-16-0326</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">O. Cerles, E. Benoit, C. Chereau, et al., Niclosamide inhibits oxaliplatin neurotoxicity while Improving Colorectal Cancer Therapeutic Response, Mol. Cancer Ther. 16 (2017) 300-311. https://doi.org/10.1158/1535-7163.MCT-16-0326.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.-K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multi-targeted therapy of cancer by niclosamide: a new application for an old drug</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>349</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8</sb:first-page>
                              <sb:last-page>14</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.canlet.2014.04.003</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">Y. Li, P.-K. Li, M.J. Roberts, et al., Multi-targeted therapy of cancer by niclosamide: A new application for an old drug, Cancer Lett. 349 (2014) 8-14. https://doi.org/10.1016/j.canlet.2014.04.003.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Walters Haygood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Arend</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gangrade</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Niclosamide analogs for treatment of ovarian cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1377</sb:first-page>
                              <sb:last-page>1385</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1097/IGC.0000000000000506</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">C.L. Walters Haygood, R.C. Arend, A. Gangrade, et al., Niclosamide analogs for treatment of ovarian cancer, Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 25 (2015) 1377-1385. https://doi.org/10.1097/IGC.0000000000000506.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.-H.</ce:given-name>
                                 <ce:surname>Chien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-C.</ce:given-name>
                                 <ce:surname>Ho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-F.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Environ. Toxicol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>659</sb:first-page>
                              <sb:last-page>669</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/tox.22551</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">M.-H. Chien, Y.-C. Ho, S.-F. Yang, et al., Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression, Environ. Toxicol. 33 (2018) 659-669. https://doi.org/10.1002/tox.22551.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Niclosamide inhibits cell growth and enhances drug sensitivity of hepatocellular carcinoma cells via STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4150</sb:first-page>
                              <sb:last-page>4155</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.7150/jca.26948</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">C. Wang, X. Zhou, H. Xu, et al., Niclosamide inhibits cell growth and enhances drug sensitivity of hepatocellular carcinoma cells via STAT3 signaling pathway, J. Cancer. 9 (2018) 4150-4155. https://doi.org/10.7150/jca.26948.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5292</sb:first-page>
                              <sb:last-page>5304</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41388-018-0340-y</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">L. Lu, J. Dong, L. Wang, et al., Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide, Oncogene. 37 (2018) 5292-5304. https://doi.org/10.1038/s41388-018-0340-y.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of O-Alkylamino tethered Niclosamide derivatives as potent and orally bioavailable anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>180</sb:first-page>
                              <sb:last-page>185</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ml3003082</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">H. Chen, Z. Yang, C. Ding, et al., Discovery of O-Alkylamino tethered Niclosamide derivatives as potent and orally bioavailable anticancer agents, ACS Med. Chem. Lett. 4 (2013) 180-185. https://doi.org/10.1021/ml3003082.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Avalle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pensa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Regis</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT1 and STAT3 in tumorigenesis: a matter of balance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JAK-STAT</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>65</sb:first-page>
                              <sb:last-page>72</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.4161/jkst.20045</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">L. Avalle, S. Pensa, G. Regis, et al., STAT1 and STAT3 in tumorigenesis: A matter of balance, JAKSTAT, 1 (2012) 65-72, doi: 10.4161/jkst.20045.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>W</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>151</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>752</sb:first-page>
                              <sb:last-page>764</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2018.03.053</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">J. Guo, W. Yu, G. Cai, W et al., Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors, Eur J Med Chem, 151 (2018) 752-764, doi: 10.1016/j.ejmech.2018.03.053.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>